Pregnancy

5-alpha reductase inhibitors, pregnancy

If administered to a woman carrying a male foetus, inhibit the development of the external genitalia of the foetus. The use is contraindicated for use in women

5-aminolevulinic acid [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, Ameluz is not recommended during pregnancy and in women of childbearing potential not using contraception.

Abacavir [1], pregnancy ---> SmPC of [1] of EMA

Placental transfer of abacavir and/or its related metabolites has been shown to occur in human.

Abacavir/lamivudine [1], pregnancy ---> SmPC of [1] of EMA

There are no data on the use of Kivexa in pregnancy, however the malformative risk is unlikely in humans based on those data.

Abacavir/lamivudine/zidovudine [1], pregnancy ---> SmPC of [1] of EMA

There are no data on the use of the medicinal product with Trizivir in pregnancy.

Abaloparatide [1], pregnancy ---> SmPC of [1] of EMA

Eladynos is contraindicated during pregnancy

Abarelix, pregnancy

It is not indicated for women

Abatacept [1], pregnancy ---> SmPC of [1] of EMA

ORENCIA should not be used in pregnant women unless clearly necessary. Women of child-bearing potential should use effective contraception during treatment with ORENCIA and up to 14 weeks after the last dose of abatacept treatment.

Abciximab, pregnancy

Should not be used during pregnancy unless clearly needed

Abemaciclib [1], pregnancy ---> SmPC of [1] of EMA

Verzenios is not recommended during pregnancy and in women of child-bearing potential not using contraception.

Abiraterone [1], pregnancy ---> SmPC of [1] of EMA

ZYTIGA is not for use in women and is contraindicated in women who are or may potentially be pregnant

Abiraterone/niraparib [1], pregnancy ---> SmPC of [1] of EMA

Akeega is not for use in women

Abrocitinib [1], pregnancy ---> SmPC of [1] of EMA

Cibinqo is contraindicated during pregnancy

Acalabrutinib [1], pregnancy ---> SmPC of [1] of EMA

Calquence should not be used during pregnancy unless the clinical condition of the woman requires treatment with acalabrutinib.

Acamprosate, pregnancy

Not recommended during the pregnancy

Acarbose [1], pregnancy ---> SmPC of [1] of eMC

The use of acarbose is contra-indicated in pregnancy

ACE inhibitors, pregnancy

The use of ACE inhibitors is not recommended during the first trimester of pregnancy. The use of ACE inhibitors is contra-indicated during the 2nd and 3rd trimester of pregnancy

Aceclofenac [1], pregnancy ---> SmPC of [1] of eMC

During the first and second trimester of pregnancy, aceclofenac should not be given unless clearly necessary. Aceclofenac is contraindicated during the third trimester of pregnancy

Acenocoumarol [1], pregnancy ---> SmPC of [1] of eMC

Should not be used during pregnancy (contra-indicated)

Acetazolamide [1], pregnancy ---> SmPC of [1] of eMC

Acetazolamide should not be used in pregnancy, especially during the first trimester.

Acetylcholine [1], pregnancy ---> SmPC of [1] of eMC

Acetylcholine should not be used in pregnant patients.

Acetylcysteine [1], pregnancy ---> SmPC of [1] of eMC

Prior to use in pregnancy, the potential risks should be balanced against the potential benefits.

Acetylsalicylic acid, pregnancy

The acetylsalicylic acid crosses the placental barrier. Contraindicated in the third trimester of pregnancy

Aciclovir [1], pregnancy ---> SmPC of [1] of eMC

The use of aciclovir should be considered only when the potential benefits outweigh the possibility of unknown risks.

Acipimox [1], pregnancy ---> SmPC of [1] of eMC

It is recommended that acipimox not be administered to women who are, or may be pregnant.

Acitretin [1], pregnancy ---> SmPC of [1] of eMC

Acitretin is contraindicated in pregnant women

Aclidinium [1], pregnancy ---> SmPC of [1] of EMA

Aclidinium bromide should only be used during pregnancy if the expected benefits outweigh the potential risks.

Aclidinium/formoterol [1], pregnancy ---> SmPC of [1] of EMA

Duaklir Genuair should only be used during pregnancy if the expected benefits outweigh the potential risks.

Activated charcoal [1], pregnancy ---> SmPC of [1] of eMC

There is no evidence to suggest that activated charcoal should not be used during pregnancy. The product is not systemically absorbed.

Adalimumab [1], pregnancy ---> SmPC of [1] of EMA

Due to its inhibition of TNF-alfa, adalimumab administered during pregnancy could affect normal immune responses in the newborn. Administration of adalimumab is not recommended during pregnancy.

Adapalene [1], pregnancy ---> SmPC of [1] of eMC

Should not be used during pregnancy.

Adefovir dipivoxil [1], pregnancy ---> SmPC of [1] of EMA

Should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus

Adenosine [1], pregnancy ---> SmPC of [1] of eMC

Adenosine is not recommended during pregnancy unless the physician considers the benefits to outweigh the potential risks.

Adipic acid, pregnancy

Strict indication

Adrenaline [1], pregnancy ---> SmPC of [1] of eMC

Adrenaline should only be used in pregnancy if the potential benefits outweigh the risks to the foetus.

Adsorbed diphtheria vaccine, pregnancy

Strict indication

Afamelanotide [1], pregnancy ---> SmPC of [1] of EMA

SCENESSE should not be used during pregnancy.

Afatinib [1], pregnancy ---> SmPC of [1] of EMA

If used during pregnancy or if the patient becomes pregnant while or after receiving GIOTRIF, she should be informed of the potential hazard to the foetus.

Aflibercept [1], pregnancy ---> SmPC of [1] of EMA

Eylea should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.

Agalsidase alfa [1], pregnancy ---> SmPC of [1] of EMA

Caution should be exercised when prescribing to pregnant women

Agalsidase beta [1], pregnancy ---> SmPC of [1] of EMA

Fabrazyme should not be used during pregnancy unless clearly necessary.

Agomelatine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Valdoxan during pregnancy.

Ajmaline, pregnancy

Ajmaline should only be administered during pregnancy on strict indication

Alanyl glutamine, pregnancy

Strict indication

Albendazole, pregnancy

Albendazole is contraindicated during pregnancy

Albiglutide [1], pregnancy ---> SmPC of [1] of EMA

Eperzan should not be used during pregnancy, and is not recommended in women of childbearing potential not using effective contraception.

Albumin tannate, pregnancy

Should not be used during pregnancy

Albutrepenonacog alfa [1], pregnancy ---> SmPC of [1] of EMA

Factor IX should be used during pregnancy and lactation only if clearly indicated.

Alclometasone [1], pregnancy ---> SmPC of [1] of eMC

Women who are pregnant will be advised not to use this medicinal product

Aldesleukin [1], pregnancy ---> SmPC of [1] of eMC

It should not be used during pregnancy unless the potential benefit to the patient justifies the potential risk to the foetus.

Alectinib [1], pregnancy ---> SmPC of [1] of EMA

Based on its mechanism of action, Alecensa may cause foetal harm when administered to a pregnant woman. Studies in animals have shown reproductive toxicity

Alemtuzumab [1], pregnancy ---> SmPC of [1] of EMA

LEMTRADA should be administered during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Alendronate/colecalciferol [1], pregnancy ---> SmPC of [1] of EMA

Studies in animals have shown hypercalcaemia and reproductive toxicity with high doses of vitamin D (see section 5.3). ADROVANCE should not be used during pregnancy.

Alendronic acid [1], pregnancy ---> SmPC of [1] of EMA

Alendronate should not be used during pregnancy.

Alendronic acid/colecalciferol [1], pregnancy ---> SmPC of [1] of EMA

Alendronic acid/colecalciferol is only intended for use in postmenopausal women and therefore it should not be used during pregnancy

Alfacalcidol [1], pregnancy ---> SmPC of [1] of eMC

Caution should be taken when prescribing to pregnant women as hypercalcaemia during pregnancy may produce congenital disorders in the offspring.

Alfatradiol, pregnancy

Contraindicated

Alfentanyl [1], pregnancy ---> SmPC of [1] of eMC

It is necessary to consider possible risks and potential advantages before administering this drug to pregnant patients.

Alfuzosin [1], pregnancy ---> SmPC of [1] of eMC

Due to the type of indication this section is not applicable.

Algeldrate, pregnancy

Contraindicated

Algeldrate/magnesium hydroxide [1], pregnancy ---> SmPC of [1] of eMC

Use of antacids should be avoided in the first trimester of pregnancy. Caution should be exercised when prescribing to pregnant women.

Alglucosidase alfa [1], pregnancy ---> SmPC of [1] of EMA

Myozyme should not be used during pregnancy unless clearly necessary.

Alimemazine [1], pregnancy ---> SmPC of [1] of eMC

Alimemazine should be avoided in pregnancy unless the physician considers it essential.

Alipogene tiparvovec [1], pregnancy ---> SmPC of [1] of EMA

Glybera should not be administered to pregnant women unless the possible benefit to the mother outweighs the possible risk to the foetus.

Alirocumab [1], pregnancy ---> SmPC of [1] of EMA

The use of Praluent is not recommended during pregnancy unless the clinical condition of the woman requires treatment with alirocumab.

Aliskiren [1], pregnancy ---> SmPC of [1] of EMA

Rasilez should not be used during the first trimester of pregnancy or in women planning to become pregnant and is contraindicated during the second and third trimesters

Aliskiren/amlodipine [1], pregnancy ---> SmPC of [1] of EMA

Rasilamlo should not be used during the first trimester of pregnancy. Rasilamlo is contraindicated during the second and third trimesters

Aliskiren/amlodipine/hydrochlorothiazide [1], pregnancy ---> SmPC of [1] of EMA

Rasitrio should not be used during the first trimester of pregnancy. Rasitrio is contraindicated during the second and third trimesters

Aliskiren/hydrochlorothiazide [1], pregnancy ---> SmPC of [1] of EMA

Rasilez HCT should not be used during the first trimester of pregnancy or in women planning to become pregnant and is contraindicated during the second and third trimesters

Alitretinoin [1], pregnancy ---> SmPC of [1] of EMA

Panretin is contraindicated (see section 4.3) in pregnancy, as alitretinoin may cause foetal harm when administered systemically to a pregnant woman.

Alizapride, pregnancy

Should not be used during pregnancy

Allethrin, pregnancy

Contraindicated in the first trimester

Allopurinol [1], pregnancy ---> SmPC of [1] of eMC

Use in pregnancy only when there is no safer alternative and when the disease itself carries risk for the mother or unborn child.

Allopurinol/lesinurad [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Duzallo during pregnancy.

Almasilate, pregnancy

Long-lasting or at high-dose treatment with antacids is contraindicated during pregnancy due to possible systemic effect

Almotriptan [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing almotriptan to pregnant women.

Aloe, pregnancy

Contraindicated

Alogliptin [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of alogliptin during pregnancy.

Alogliptin/metformin [1], pregnancy ---> SmPC of [1] of EMA

Vipdomet should not be used during pregnancy.

Alogliptin/pioglitazone [1], pregnancy ---> SmPC of [1] of EMA

Incresync should not be used during pregnancy.

Alpelisib [1], pregnancy ---> SmPC of [1] of EMA

Piqray is not recommended during pregnancy and in women of childbearing potential not using contraception.

Alpha-1 proteinase inhibitor, pregnancy

Caution is recommended

Alpha1-antytripsin, pregnancy

Caution is recommended in pregnant women

Alprazolam [1], pregnancy ---> SmPC of [1] of eMC

Alprazolam should not be used during pregnancy unless the clinical condition of the woman requires treatment with alprazolam.

Alprostadil, pregnancy

It is not for use in women.

Alteplase [1], pregnancy ---> SmPC of [1] of eMC

In cases of an acute life-threatening disease the benefit has to be evaluated against the potential risk.

Aluminium acetotartrate, pregnancy

Strict indication

Aluminium chloride, pregnancy

This drug should not be used during pregnancy because there is no experience

Aluminium hydroxide [1], pregnancy ---> SmPC of [1] of eMC

It should not be used during pregnancy unless clearly necessary.

Aluminium oxide/magnesium hydroxide [1], pregnancy ---> SmPC of [1] of eMC

Use of antacids should be avoided in the first trimester of pregnancy. Caution should be exercised when prescribing to pregnant women.

Aluminium, pregnancy

Only short-term use

Amantadine [1], pregnancy ---> SmPC of [1] of eMC

Amantadine is contraindicated during pregnancy and in women wishing to become pregnant.

Ambrisentan [1], pregnancy ---> SmPC of [1] of EMA

Ambrisentan is contraindicated in pregnancy

Ambroxol, pregnancy

Do not administer during the first trimester of pregnancy.

Amcinonide, pregnancy

Strict indication, especially in the first trimester

Amezinium, pregnancy

Strict indication

Amfepramone, pregnancy

Amfepramone must not be used during the whole pregnancy

Amifampridine [1], pregnancy ---> SmPC of [1] of EMA

FIRDAPSE should not be used during pregnancy.

Amifostine, pregnancy

Contraindicated

Amikacine [1], pregnancy ---> SmPC of [1] of eMC

Amikacin should be administered to pregnant women and neonatal infants only when clearly needed and under medical supervision

Amiloride [1], pregnancy ---> SmPC of [1] of eMC

Amiloride is not recommended for use during pregnancy due to limited clinical experience.

Amiloride/hydrochlorothiazide [1], pregnancy ---> SmPC of [1] of eMC

There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects

Aminobenzoate potassium [1], pregnancy ---> SmPC of [1] of eMC

No information is available on this, therefore it is not recommended.

Aminoglycoside antibiotics, pregnancy ---> SmPC of [amikacine] of eMC

The aminoglycoside antibiotic crosses the placenta

Aminomethylbenzoic acid, pregnancy

Strict indication

Aminophylline [1], pregnancy ---> SmPC of [1] of eMC

As with other drugs, aminophylline should only be used during pregnancy if considered essential by the physician. Theophylline crosses the placenta.

Aminosalicyclic acid, pregnancy

Strict indication

Amiodarone [1], pregnancy ---> SmPC of [1] of eMC

In view of its effect on the foetal thyroid gland, amiodarone is contraindicated during pregnancy, except in exceptional circumstances.

Amisulpride [1], pregnancy ---> SmPC of [1] of eMC

Use of the drug is not recommended during pregnancy unless the benefits justify the potential risks.

Amitriptyline [1], pregnancy ---> SmPC of [1] of eMC

Amitriptyline should not be used during the first and third trimester and the hazards to the foetus, child or mother must be evaluated when considering the possible benefits of amitriptyline therapy during pregnancy.

Amitriptylinoxide, pregnancy

Amitriptylinoxide should not be used during pregnancy, especially in the first and last trimester of pregnancy, unless clearly needed

Amivantamab [1], pregnancy ---> SmPC of [1] of EMA

Amivantamab could cause foetal harm when administered to a pregnant woman. If the patient becomes pregnant while taking this medicinal product the patient should be informed of the potential risk to the foetus

Amlodipine, pregnancy ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA

Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.

Amlodipine/valsartan [1], pregnancy ---> SmPC of [1] of EMA

The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy. The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy

Amlodipine/valsartan [1], pregnancy ---> SmPC of [1] of EMA

The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy. The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy

Amlodipine/valsartan/hydrochlorothiazide [1], pregnancy ---> SmPC of [1] of EMA

Based on the existing data with the components, the use of Dafiro HCT is not recommended during first trimester and contraindicated during the second and third trimester of pregnancy

Ammonium chloride, pregnancy

Contraindicated

Amorolfine [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure it is preferable to avoid the use of amorolfine medicated nail lacquer during pregnancy.

Amoxicillin [1], pregnancy ---> SmPC of [1] of eMC

Amoxicillin passes the placenta. Caution should be exercised when prescribing to pregnant women.

Amoxicillin/clavulanic acid [1], pregnancy ---> SmPC of [1] of eMC

Use should be avoided during pregnancy, unless considered essential by the physician.

Amphotericin, pregnancy

Amphotericin should be used during pregnancy only if the possible benefits to be derived outweigh the potential risks involved.

Ampicillin [1], pregnancy ---> SmPC of [1] of eMC

When antibiotic therapy is required during pregnancy, ampicillin may be considered appropriate.

Ampicillin/sulbactam, pregnancy

As a precautionary measure, the use of ampicillin during pregnancy should be based on individual risk/benefit assessment

Amprenavir [1], pregnancy ---> SmPC of [1] of EMA

This medicinal product should be used during pregnancy only after careful weighing of the potential benefits compared to the potential risk to the foetus.

Amsacrine, pregnancy

Contraindicated

Anagrelide [1], pregnancy ---> SmPC of [1] of EMA

Xagrid is not recommended during pregnancy. If anagrelide is used during pregnancy, or if the patient becomes pregnant while using the medicinal product, she should be advised of the potential risk to the foetus.

Anakinra [1], pregnancy ---> SmPC of [1] of EMA

Kineret is not recommended during pregnancy and in women of childbearing potential not using contraception.

Anastrozole [1], pregnancy ---> SmPC of [1] of eMC

Anastrozole is contraindicated in pregnant women.

Andexanet alfa [1], pregnancy ---> SmPC of [1] of EMA

Andexanet alfa is not recommended during pregnancy or in women of childbearing potential not using contraception.

Angiotensin II [1], pregnancy ---> SmPC of [1] of EMA

Use during pregnancy should be avoided if possible and the potential benefit to the patient weighed against any possible risk to the foetus.

Anidulafungin [1], pregnancy ---> SmPC of [1] of EMA

Not recommended during the pregnancy

Anifrolumab [1], pregnancy ---> SmPC of [1] of EMA

Saphnelo is not recommended during pregnancy and in women of childbearing potential not using contraception, unless the possible benefit justifies the potential risk.

Antacids, pregnancy

Use of antacids should be avoided in the first trimester of pregnancy.

Anthracyclines, pregnancy

Contraindicated

Anticholinergics, pregnancy

Strict indication

Antimuscarinic agents, pregnancy

Strict indication

Antithrombin alfa [1], pregnancy ---> SmPC of [1] of EMA

Antithrombin alfa should not be used in pregnant women.

Antithrombin III, pregnancy

Strict indication

Apalutamide [1], pregnancy ---> SmPC of [1] of EMA

Erleada is contraindicated in women who are or may become pregnant. Based on its mechanism of action, Erleada may cause foetal harm when administered during pregnancy.

Apixaban [1], pregnancy ---> SmPC of [1] of EMA

Apixaban is not recommended during pregnancy.

Apomorphine [1], pregnancy ---> SmPC of [1] of eMC

Apomorphine should not be used in pregnancy unless clearly necessary.

Apraclonidine [1], pregnancy ---> SmPC of [1] of eMC

Apraclonidine is not recommended during pregnancy

Apremilast [1], pregnancy ---> SmPC of [1] of EMA

Apremilast is contraindicated during pregnancy.

Aprepitant [1], pregnancy ---> SmPC of [1] of EMA

EMEND should not be used during pregnancy unless clearly necessary.

Aprotinin, pregnancy

Aprotinin should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.

Argatroban [1], pregnancy ---> SmPC of [1] of eMC

Argatroban should be used during pregnancy only if treatment is clearly necessary.

Arginine/lysine [1], pregnancy ---> SmPC of [1] of EMA

There are no data on the use of arginine and lysine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity

Aripiprazole [1], pregnancy ---> SmPC of [1] of EMA

Should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the foetus

Arsenic trioxide [1], pregnancy ---> SmPC of [1] of EMA

If this medicine is used during pregnancy or if the patient becomes pregnant while taking this product, the patient must be informed of the potential harm to the foetus

Artemether, pregnancy

Strict indication

Artemether/lumefantrine [1], pregnancy ---> SmPC of [1] of eMC

It must not be used during the 1st pregnancy trimester in situations where other suitable and effective antimalarials are available. During the 2nd and 3rd trimester, treatment should only be considered if the benefit outweighs the risk

Artesunate [1], pregnancy ---> SmPC of [1] of EMA

The use of Artesunate Amivas in the first trimester is not recommended. As a precautionary measure, it is preferable to avoid the use of Artesunate Amivas during the second or third trimester of pregnancy

Articaine/epinephrine, pregnancy

It may only be used during pregnancy after a careful benefit/risk assessment

Asciminib [1], pregnancy ---> SmPC of [1] of EMA

Asciminib is not recommended during pregnancy and in women of childbearing potential not using contraception.

Ascorbic acid, pregnancy

Ascorbic acid in doses greater than 1 g should not be administered during pregnancy as the effect of large doses on the foetus is not known.

Asenapine [1], pregnancy ---> SmPC of [1] of EMA

Sycrest should not be used during pregnancy unless clearly necessary and only if the potential benefit outweighs the potential risk to the foetus.

Asfotase alfa [1], pregnancy ---> SmPC of [1] of EMA

Asfotase alfa is not recommended during pregnancy and in women of childbearing potential not using contraception.

Asparaginase [1], pregnancy ---> SmPC of [1] of EMA

Spectrila should not be used during pregnancy unless the clinical condition of the woman requires treatment with asparaginase.

Ataluren [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is recommended to avoid the use of ataluren during pregnancy.

Atazanavir [1], pregnancy ---> SmPC of [1] of EMA

The use of REYATAZ with ritonavir may be considered during pregnancy only if the potential benefit justifies the potential risk.

Atazanavir/cobicistat [1], pregnancy ---> SmPC of [1] of EMA

The use of EVOTAZ may be considered during pregnancy only if the potential benefit justifies the potential risk.

Atazanavir/ritonavir, pregnancy ---> SmPC of [atazanavir] of EMA

The use of REYATAZ with ritonavir may be considered during pregnancy only if the potential benefit justifies the potential risk.

Atenolol [1], pregnancy ---> SmPC of [1] of eMC

Atenolol crosses the placental barrier. Adverse effects (especially hypoglycaemia and bradycardia) may occur in foetus and neonate. There is an increased risk of cardiac and pulmonary complications in the neonate in the postnatal period.

Atenolol/chlortalidone [1], pregnancy ---> SmPC of [1] of eMC

It must not be given during pregnancy

Atenolol/nifedipine [1], pregnancy ---> SmPC of [1] of eMC

Atenolol/nifedipine is contraindicated during pregnancy

Atezolizumab [1], pregnancy ---> SmPC of [1] of EMA

Atezolizumab should not be used during pregnancy unless the clinical condition of the woman requires treatment with atezolizumab.

Atidarsagene [1], pregnancy ---> SmPC of [1] of EMA

As Libmeldy is not intended for use in adults, human data on use during pregnancy or lactation and animal reproduction studies are not available.

Atomoxetine, pregnancy

Atomoxetine should not be used during pregnancy unless the potential benefit justifies the potential risk to the foetus.

Atorvastatin [1], pregnancy ---> SmPC of [1] of eMC

Atorvastatin is contraindicated during pregnancy

Atosiban [1], pregnancy ---> SmPC of [1] of EMA

Atosiban should only be used when pre-term labour has been diagnosed between 24 and 33 completed weeks of gestation

Atovaquone [1], pregnancy ---> SmPC of [1] of eMC

Atovaquone should not be used during pregnancy unless the benefit of treatment to the mother outweighs any possible risk to the developing foetus.

Atovaquone/proguanil [1], pregnancy ---> SmPC of [1] of eMC

The use in pregnancy should only be considered if the expected benefit to the mother outweighs any potential risk to the foetus.

Atracurium [1], pregnancy ---> SmPC of [1] of eMC

Atracurium besilate should only be administered during pregnancy after careful risk-benefit assessment.

Atropine [1], pregnancy ---> SmPC of [1] of eMC

Atropine should not be used during pregnancy unless clearly necessary.

Aurothiomalate, pregnancy

Aurothiomalate should not be used during pregnancy because gold crosses the placenta

Autologous anti-CD19-transduced CD3+ cells [1], pregnancy ---> SmPC of [1] of EMA

Tecartus is not recommended for women who are pregnant, or for women of childbearing potential not using contraception. Pregnant women should be advised on the potential risks to the foetus.

Autologous chondrocyte [1], pregnancy ---> SmPC of [1] of EMA

It is not recommended during pregnancy.

Avacopan [1], pregnancy ---> SmPC of [1] of EMA

Avacopan is not recommended during pregnancy and in women of childbearing potential not using contraception.

Avalglucosidase alfa [1], pregnancy ---> SmPC of [1] of EMA

Nexviadyme should be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the foetus.

Avanafil [1], pregnancy ---> SmPC of [1] of EMA

Spedra is not indicated for use in women.

Avapritinib [1], pregnancy ---> SmPC of [1] of EMA

AYVAKYT is not recommended during pregnancy and in women of childbearing potential not using contraception. The patient should be advised of the potential risk to the foetus.

Avatrombopag [1], pregnancy ---> SmPC of [1] of EMA

Doptelet is not recommended during pregnancy and in women of childbearing  potential not using contraception.

Avelumab [1], pregnancy ---> SmPC of [1] of EMA

It is not recommended to use avelumab during pregnancy unless the clinical condition of the woman requires treatment with avelumab.

Axicabtagene ciloleucel [1], pregnancy ---> SmPC of [1] of EMA

YESCARTA is not recommended for women who are pregnant, or for women of childbearing potential not using contraception

Axitinib [1], pregnancy ---> SmPC of [1] of EMA

Axitinib should not be used during pregnancy unless the clinical condition of the woman requires treatment with this medicinal product.

Azacitidine [1], pregnancy ---> SmPC of [1] of EMA

Azacitidine should not be used during pregnancy, especially during the first trimester, unless clearly necessary.

Azapropazone, pregnancy

It use should be avoided during the pregnancy

Azathioprine [1], pregnancy ---> SmPC of [1] of eMC

Azathioprine should not be given to patients who are pregnant or likely to become pregnant in the near future without careful assessment of risk versus benefit.

Azelaic acid, pregnancy

Strict indication

Azelastine [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when using azelastine during pregnancy.

Azilsartan medoxomil [1], pregnancy ---> SmPC of [1] of EMA

The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy. The use of angiotensin II receptor antagonists is contraindicated during the second and third trimester of pregnancy

Azilsartan [1], pregnancy ---> SmPC of [1] of EMA

Is not recommended during the first trimester of pregnancy. Is contraindicated during the second and third trimesters of pregnancy.

Azithromycin [1], pregnancy ---> SmPC of [1] of eMC

Azithromycin should only be used during pregnancy if the benefit outweighs the risk.

Aztreonam [1], pregnancy ---> SmPC of [1] of EMA

Cayston should not be used during pregnancy unless the clinical condition of the woman requires treatment with aztreonam.

Baclofen [1], pregnancy ---> SmPC of [1] of eMC

Baclofen should not be used during pregnancy, unless the advantages of the therapy for the mother outweigh the possible risks to the child.

Baloxavir [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Xofluza during pregnancy.

Balsalazide [1], pregnancy ---> SmPC of [1] of eMC

Should not be given to pregnant women

Bambuterol [1], pregnancy ---> SmPC of [1] of eMC

Caution is recommended during the first trimester of pregnancy. Beta-agonists should be used with caution at the end of pregnancy because of the tocolytic effect.

Bamethane, pregnancy

In the first trimester should only be used with great caution. It should be avoided short before delivery due to the tocolytic effect

Bamipine, pregnancy

Contraindicated

Baricitinib [1], pregnancy ---> SmPC of [1] of EMA

Olumiant is contraindicated during pregnancy

Barnidipine, pregnancy

Should only be used during pregnancy if the expected benefits outweigh the potential risks.

Basiliximab [1], pregnancy ---> SmPC of [1] of EMA

Simulect is contraindicated in pregnancy

Bazedoxifene [1], pregnancy ---> SmPC of [1] of EMA

CONBRIZA is only for use in postmenopausal women. It is contraindicated in women of child-bearing potential

BCG intravesical [1], pregnancy ---> SmPC of [1] of eMC

BCG intravesical instillation for carcinoma of the bladder is contraindicated during pregnancy

Becaplermin [1], pregnancy ---> SmPC of [1] of EMA

Should not be used during pregnancy

Beclometasone [1], pregnancy ---> SmPC of [1] of eMC

Beclometasone should not be used in pregnancy, unless strictly indicated after a careful risk / benefit evaluation.

Beclometasone/formoterol/glycopyrronium [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Trimbow during pregnancy and during labour.

Bedaquiline [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is recommended to avoid the use of Sirturo during pregnancy unless the benefit of therapy is considered to outweigh the risks.

Belantamab [1], pregnancy ---> SmPC of [1] of EMA

BLENREP should not be used during pregnancy unless the benefit to the mother outweighs the potential risks to the foetus. If a pregnant woman needs to be treated she should be clearly advised on the potential risk to the foetus.

Belatacept [1], pregnancy ---> SmPC of [1] of EMA

Belatacept should not be used in pregnant women unless clearly necessary.

Belimumab [1], pregnancy ---> SmPC of [1] of EMA

Benlysta should not be used during pregnancy unless the potential benefit justifies the potential risk to the foetus.

Bemetizide, pregnancy

Contraindicated

Bemiparin, pregnancy

For bemiparin, no clinical data on exposed pregnancies are available. Therefore, caution should be exercised when prescribing to pregnant women.

Bempedoic acid [1], pregnancy ---> SmPC of [1] of EMA

Nilemdo is contraindicated during pregnancy

Bempedoic acid/ezetimibe [1], pregnancy ---> SmPC of [1] of EMA

Nustendi is contraindicated during pregnancy

Benazepril, pregnancy

The use of ACE inhibitors is not recommended during the first trimester of pregnancy. The use of ACE inhibitors is contra-indicated during the 2nd and 3rd trimester of pregnancy

Benazepril/hydrochlorothiazide, pregnancy

This medicinal product is contraindicated during pregnancy

Bendamustine [1], pregnancy ---> SmPC of [1] of eMC

During pregnancy bendamustine should not be used unless clearly necessary

Bendroflumethiazide [1], pregnancy ---> SmPC of [1] of eMC

Diuretics are best avoided for the management of oedema of pregnancy or hypertension in pregnancy as their use may be associated with hypokalaemia, increased blood viscosity and reduced placental perfusion.

Benperidol [1], pregnancy ---> SmPC of [1] of eMC

As with other drugs, it is not advisable to administer benperidol in pregnancy.

Benproperine, pregnancy

Strict indication in the first trimester

Benralizumab [1], pregnancy ---> SmPC of [1] of EMA

It is preferable to avoid the use of Fasenra during pregnancy. Its administration to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus.

Benzbromarone, pregnancy

The administration of benzbromarone during pregnancy is contraindicated

Benzocaine [1], pregnancy ---> SmPC of [1] of eMC

No clinical data are available on the use of this product during pregnancy

Benzoyl peroxide [1], pregnancy ---> SmPC of [1] of eMC

Benzoyl peroxide should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.

Benzydamine, pregnancy

Strict indication

Benzyl benzoate, pregnancy

Strict indication

Benzyl nicotinate, pregnancy

Full bath: Contraindicated

Berotralstat [1], pregnancy ---> SmPC of [1] of EMA

Berotralstat is not recommended during pregnancy.

Besilesomab [1], pregnancy ---> SmPC of [1] of EMA

The use of besilesomab is contraindicated in pregnant women

Beta-acetyldigoxin, pregnancy

The pregnant woman should be carefully monitored during the pregnancy

Beta2-adrenergic agonists, pregnancy

The beta2-adrenergic agonists may inhibit labour due to a relaxant effect on uterine smooth muscle. Should only be used if the expected benefits outweigh the potential risks.

Betacarotene, pregnancy

Strict indication

Betahistidine [1], pregnancy ---> SmPC of [1] of eMC

Betahistine should not be used during pregnancy unless clearly necessary.

Betahistine [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure, it is preferable to avoid the use of betahistine during pregnancy.

Betaine anhydrous [1], pregnancy ---> SmPC of [1] of EMA

Cystadane should not be used during pregnancy unless clearly necessary

Betamethasone [1], pregnancy ---> SmPC of [1] of eMC

The administration of betamethasone valerate during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the foetus.

Betaxolol [1], pregnancy ---> SmPC of [1] of eMC

Betaxolol should not be used during pregnancy unless clearly necessary.

Bethanechol [1], pregnancy ---> SmPC of [1] of eMC

Should not be used during pregnancy

Bevacizumab [1], pregnancy ---> SmPC of [1] of EMA

Avastin is contraindicated in pregnancy

Bexarotene [1], pregnancy ---> SmPC of [1] of EMA

Bexarotene is contraindicated in pregnancy

Bezafibrate [1], pregnancy ---> SmPC of [1] of eMC

There are limited data from the use of bezafibrate in pregnant women. It is not recommended during pregnancy and in women of childbearing potential not using contraception

Bezlotoxumab [1], pregnancy ---> SmPC of [1] of EMA

ZINPLAVA should not be used during pregnancy unless the clinical condition of the woman requires treatment with bezlotoxumab.

Bicalutamide [1], pregnancy ---> SmPC of [1] of eMC

Not applicable, since this medicinal product is not used in women.

Bictegravir/emtricitabine/tenofovir alafenamide [1], pregnancy ---> SmPC of [1] of EMA

Biktarvy should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Bifonazole, pregnancy

Strict indication

Bilastine [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure, it is preferable to avoid the use of bilastine during pregnancy

Bimatoprost [1], pregnancy ---> SmPC of [1] of EMA

Bimatoprost should not be used during pregnancy unless clearly necessary.

Bimatoprost/timolol [1], pregnancy ---> SmPC of [1] of EMA

GANFORT should not be used during pregnancy unless clearly necessary.

Bimekizumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Bimzelx during pregnancy.

Binimetinib [1], pregnancy ---> SmPC of [1] of EMA

Binimetinib is not recommended during pregnancy and in women of childbearing potential not using contraception.

Biotin, pregnancy

There has been described no problems with the intake of the recommended doses

Biperiden, pregnancy

The use of biperiden during pregnancy should be based on individual risk/benefit assessment

Biphosphonates, pregnancy

Contraindicated

Bisacodyl [1], pregnancy ---> SmPC of [1] of eMC

Bisacodyl should not be taken in pregnancy, especially the first trimester, unless the expected benefit is thought to outweigh any possible risk and only on medical advice.

Bisoprolol [1], pregnancy ---> SmPC of [1] of eMC

Bisoprolol is not recommended during pregnancy unless clearly necessary.

Bivalirudin [1], pregnancy ---> SmPC of [1] of EMA

Angiox should not be used during pregnancy unless the clinical condition of the woman requires treatment with bivalirudin.

Black cohosh, pregnancy

Contraindicated

Bleomycin [1], pregnancy ---> SmPC of [1] of eMC

Bleomycin should not normally be administered to patients who are pregnant

Blinatumomab [1], pregnancy ---> SmPC of [1] of EMA

Blinatumomab should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.

Boceprevir [1], pregnancy ---> SmPC of [1] of EMA

Boceprevir in combination with ribavirin and peginterferon alfa is contraindicated in women who are pregnant

Boldo, pregnancy

Contraindicated

Bornaprine, pregnancy

Administration during pregnancy should be avoided

Bortezomib [1], pregnancy ---> SmPC of [1] of EMA

VELCADE should not be used during pregnancy unless the clinical condition of the woman requires treatment with VELCADE.

Bosentan [1], pregnancy ---> SmPC of [1] of EMA

Tracleer is contraindicated in pregnancy

Bosutinib [1], pregnancy ---> SmPC of [1] of EMA

Bosulif is not recommended for use during pregnancy, or in women of childbearing potential not using contraception.

Botulinum toxin type A [1], pregnancy ---> SmPC of [1] of EMA

NUCEIVA is not recommended during pregnancy and in women of childbearing potential not using contraception.

Botulinum toxin type B [1], pregnancy ---> SmPC of [1] of EMA

It should not be used during pregnancy unless the clinical condition of the woman requires treatment with Botulinum Toxin Type B.

Botulinus toxin, pregnancy

Should not be used during pregnancy

Brentuximab vedotin [1], pregnancy ---> SmPC of [1] of EMA

Brentuximab vedotin should not be used during pregnancy unless the benefit to the mother outweighs the potential risks to the foetus. If a pregnant woman needs to be treated she should be clearly advised on the potential risk to the foetus.

Brexpiprazole [1], pregnancy ---> SmPC of [1] of EMA

Brexpiprazole is not recommended during pregnancy and in women of childbearing potential not using contraception.

Brigatinib [1], pregnancy ---> SmPC of [1] of EMA

Alunbrig may cause foetal harm when administered to a pregnant woman. Alunbrig should not be used during pregnancy unless the clinical condition of the mother requires treatment.

Brimonidine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Mirvaso during pregnancy.

Brinzolamide [1], pregnancy ---> SmPC of [1] of EMA

AZOPT is not recommended during pregnancy and in women of childbearing potential not using contraception.

Brinzolamide/brimonidine [1], pregnancy ---> SmPC of [1] of EMA

SIMBRINZA is not recommended during pregnancy and in women of child bearing potential not using contraception.

Brinzolamide/timolol [1], pregnancy ---> SmPC of [1] of EMA

Brinzolamide/timolol should not be used during pregnancy unless clearly necessary.

Brivaracetam [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, brivaracetam should not be used during pregnancy unless clinically necessary i.e. (if the benefit to the mother clearly outweighs the potential risk to the foetus).

Brivudine, pregnancy

Contraindicated during pregnancy

Brodalumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Kyntheum in pregnancy.

Brolucizumab [1], pregnancy ---> SmPC of [1] of EMA

Although the systemic exposure after ocular administration is very low, brolucizumab should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.

Bromazepam, pregnancy

Bromazepam should not be used in pregnant women unless clearly necessary

Bromelain, pregnancy

Bromelain should not be used during pregnancy

Bromfenac [1], pregnancy ---> SmPC of [1] of EMA

Since the systemic exposure in non-pregnant women is negligible after treatment with Yellox, the risk during pregnancy could be considered low.

Bromhexine, pregnancy

Bromhexine crosses the placental barrier. As a precautionary measure, it is preferable to avoid the use of bromhexine during pregnancy.

Bromocriptine [1], pregnancy ---> SmPC of [1] of eMC

If pregnancy occurs it is generally advisable to withdraw bromocriptine after the first missed menstrual period.

Bromperidol, pregnancy

Strict indication

Brotizolam, pregnancy

Brotizolam should not be used during pregnancy

Brovanexine, pregnancy

The administration during pregnancy is not recommended

Budesonide [1], pregnancy ---> SmPC of [1] of EMA

Administration during pregnancy should be avoided unless there are compelling reasons for therapy with Jorveza.

Budesonide/formoterol [1], pregnancy ---> SmPC of [1] of EMA

During pregnancy, a fixed-dose combination therapy of budesonide and formoterol fumarate dihydrate should only be used when the benefits outweigh the potential risks.

Budipine, pregnancy

Budipine should not be used during pregnancy

Buflomedil, pregnancy

Buflomedil should not be used during pregnancy

Bulevirtide [1], pregnancy ---> SmPC of [1] of EMA

As a precautious measure, it is preferable to avoid the use of bulevirtide during pregnancy and in women of child-bearing age who do not use contraception.

Bumadizone, pregnancy

Not recommended during the pregnancy

Bumetanide [1], pregnancy ---> SmPC of [1] of eMC

Although tests in four animal species have shown no teratogenic effects, the ordinary precaution of avoiding use of bumetanide in the first trimester of pregnancy should at present be observed.

Bunazosin, pregnancy

Contraindicated

Bupivacaine [1], pregnancy ---> SmPC of [1] of eMC

Bupivacaine should not be given in early pregnancy unless the benefits are considered to outweigh the risks.

Bupivacaine/meloxicam [1], pregnancy ---> SmPC of [1] of EMA

Due to the meloxicam content, Zynrelef is contraindicated during the third trimester of pregnancy. During the first and second trimester of pregnancy, meloxicam should not be given unless clearly necessary.

Buprenorphine [1], pregnancy ---> SmPC of [1] of EMA

Buprenorphine should be used during pregnancy only if the potential benefit outweighs the potential risk to the foetus.

Buprenorphine/naloxone [1], pregnancy ---> SmPC of [1] of EMA

Buprenorphine/naloxone should be used during pregnancy only if the potential benefit outweighs the potential risk to the foetus.

Bupropion [1], pregnancy ---> SmPC of [1] of eMC

Bupropion should not be used in pregnancy. Pregnant women should be encouraged to quit smoking without the use of pharmacotherapy.

Burosumab [1], pregnancy ---> SmPC of [1] of EMA

CRYSVITA is not recommended during pregnancy and in women of childbearing potential not using contraception.

Buserelin [1], pregnancy ---> SmPC of [1] of eMC

It is contraindicated in pregnancy.

Buspirone [1], pregnancy ---> SmPC of [1] of eMC

Buspirone is contraindicated in pregnancy

Busulfan [1], pregnancy ---> SmPC of [1] of EMA

Busulfan is contraindicated in pregnancy

Butylscopolamine [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure hyoscine butylbromide is not recommended during pregnancy.

C1 inhibitor [1], pregnancy ---> SmPC of [1] of EMA

Cinryze should be given to pregnant women only if clearly indicated

Cabazitaxel [1], pregnancy ---> SmPC of [1] of EMA

Cabazitaxel is not recommended during pregnancy and in women of childbearing potential not using contraception.

Cabergoline [1], pregnancy ---> SmPC of [1] of eMC

Cabergoline should only be used during pregnancy if clearly indicated and after an accurate benefit/risk evaluation.

Cabotegravir [1], pregnancy ---> SmPC of [1] of EMA

Vocabria injection is not recommended during pregnancy unless the expected benefit justifies the potential risk to the foetus. Cabotegravir has been detected in systemic circulation for up to 12 months or longer after an injection

Cabozantinib [1], pregnancy ---> SmPC of [1] of EMA

Cabozantinib should not be used during pregnancy unless the clinical condition of the woman requires treatment with cabozantinib.

Caffeine [1], pregnancy ---> SmPC of [1] of EMA

Caffeine readily crosses the placenta into the foetal circulation

Calcifediol, pregnancy

Strict indication

Calcipotriol [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure, it is preferable to avoid the use of calcipotriol during pregnancy.

Calcitonin  preparations [1], pregnancy ---> SmPC of [1] of EMA

Should be used during pregnancy only if treatment is considered absolutely essential by the physician

Calcitonin [1], pregnancy ---> SmPC of [1] of EMA

Calcitonin should be used during pregnancy only if treatment is considered absolutely essential by the physician.

Calcitriol [1], pregnancy ---> SmPC of [1] of eMC

Calcitriol should be used during pregnancy only if the benefits outweigh the potential risk to the foetus.

Calcium acetate [1], pregnancy ---> SmPC of [1] of eMC

Harmful effects on humans due to calcium taken during pregnancy have not been reported.

Calcium carbonate [1], pregnancy ---> SmPC of [1] of eMC

During pregnancy treatment with calcium carbonate should be under the direction of a physician.

Calcium carbonate/cholecalciferol [1], pregnancy ---> SmPC of [1] of eMC

There have been no studies on the use of this medicinal product in human pregnancy and lactation. In humans, long term hypercalcaemia can lead to physical and mental retardation in a new born child.

Calcium chloride [1], pregnancy ---> SmPC of [1] of eMC

Calcium chloride crosses the placenta. The benefits of administration must outweigh any potential risk.

Calcium folinate [1], pregnancy ---> SmPC of [1] of eMC

There are no indications that folic acid induces harmful effects if administered during pregnancy.

Calcium gluconate [1], pregnancy ---> SmPC of [1] of eMC

The likelihood of hypercalcaemia is increased in pregnant women in whom calcium and vitamin D are co-administered.

Canagliflozin [1], pregnancy ---> SmPC of [1] of EMA

Canagliflozin should not be used during pregnancy. When pregnancy is detected, treatment with canagliflozin should be discontinued.

Canagliflozin/metformin [1], pregnancy ---> SmPC of [1] of EMA

Vokanamet should not be used during pregnancy. When pregnancy is detected, treatment with Vokanamet should be discontinued.

Canakinumab [1], pregnancy ---> SmPC of [1] of EMA

Women who are pregnant or who desire to become pregnant should therefore only be treated after a thorough benefit-risk evaluation

Candesartan cilexetil [1], pregnancy ---> SmPC of [1] of eMC

The use of AIIRAs is not recommended during the first trimester of pregnancy. The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy

Candesartan [1], pregnancy ---> SmPC of [1] of EMA

The use of AIIRAs is not recommended during the first trimester of pregnancy. The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy

Cangrelor [1], pregnancy ---> SmPC of [1] of EMA

Kengrexal should not be used during pregnancy.

Cannabidiol [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, cannabidiol should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the foetus.

Capecitabine [1], pregnancy ---> SmPC of [1] of EMA

Capecitabine is contraindicated during pregnancy.

Caplacizumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Cablivi during pregnancy.

Capmatinib [1], pregnancy ---> SmPC of [1] of EMA

Tabrecta should not be used during pregnancy unless the clinical condition of the woman requires treatment with capmatinib. The pregnancy status of women of childbearing potential should be verified prior to starting treatment with Tabrecta.

Capsaicin [1], pregnancy ---> SmPC of [1] of EMA

Caution should be exercised when prescribing to pregnant women

Captopril [1], pregnancy ---> SmPC of [1] of eMC

The use of ACE inhibitors is not recommended during the first trimester of pregnancy. The use of ACE inhibitors is contraindicated during the second and third trimesters of pregnancy

Carbachol, pregnancy

Strict indication

Carbaldrate, pregnancy

Only short-term use

Carbamazepine [1], pregnancy ---> SmPC of [1] of eMC

Pregnant women with epilepsy should be treated with special care.

Carbenoxolone, pregnancy

This medicinal product should not be used during pregnancy

Carbetocin [1], pregnancy ---> SmPC of [1] of eMC

Carbetocin is contraindicated during pregnancy and must not be used for the induction of labour

Carbidopa, pregnancy

Should not be used during pregnancy

Carbimazole [1], pregnancy ---> SmPC of [1] of eMC

The use of carbimazole in non-pregnant women of childbearing potential should be based on individual risk/benefit assessment

Carbocisteine [1], pregnancy ---> SmPC of [1] of eMC

Carbocisteine is not recommended during the first trimester of pregnancy.

Carbomer [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing to pregnant or breast-feeding women.

Carboplatin [1], pregnancy ---> SmPC of [1] of eMC

Carboplatin has been shown to be an embryo toxin and teratogen in rats and mutagenic in vivo and in vitro. Carboplatin should not be used during pregnancy unless clearly indicated.

Carfilzomib [1], pregnancy ---> SmPC of [1] of EMA

Kyprolis should not be used during pregnancy unless the potential benefit outweighs the potential risk for foetus.

Carglumic acid [1], pregnancy ---> SmPC of [1] of EMA

Caution should be exercised when prescribing to pregnant women

Cariprazine [1], pregnancy ---> SmPC of [1] of EMA

Reagila is not recommended during pregnancy and in women of childbearing potential not using effective contraception.

Carisoprodol, pregnancy

The use of carisoprodol in pregnancy is not recommended.

Carmellose, pregnancy

Carmellose can be used in pregnancy

Carmustine [1], pregnancy ---> SmPC of [1] of EMA

Carmustine should not be administered to patients who are pregnant.

Caroverine, pregnancy

Caution is recommended

Carteolol [1], pregnancy ---> SmPC of [1] of eMC

Carteolol should not be used during pregnancy unless clearly necessary.

Carvedilol [1], pregnancy ---> SmPC of [1] of eMC

Carvedilol should not be used during pregnancy unless clearly necessary (that is if the potential benefit for the mother outweighs the potential risk for the fetus/neonate).

Cascara bark, pregnancy

Contraindicated

Casirivimab/imdevimab [1], pregnancy ---> SmPC of [1] of EMA

Ronapreve should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the foetus considering all associated health factors.

Caspofungin [1], pregnancy ---> SmPC of [1] of EMA

Caspofungin should not be used during pregnancy unless clearly needed

Cathine, pregnancy

The medicinal product is contraindicated during pregnancy

Catridecacog [1], pregnancy ---> SmPC of [1] of EMA

Based on the therapeutic need the use of NovoThirteen as a replacement therapy may be considered during pregnancy.

Catumaxomab [1], pregnancy ---> SmPC of [1] of EMA

Removab is not recommended during pregnancy and in women of childbearing potential not using contraception.

Cefaclor [1], pregnancy ---> SmPC of [1] of eMC

Since there are no adequate or well-controlled studies in pregnant women, caution should be exercised when prescribing for the pregnant patient.

Cefadroxil [1], pregnancy ---> SmPC of [1] of eMC

The use of cefadroxil during pregnancy should be handled very strictly.

Cefazolin, pregnancy

Cefazolin crosses the placental barrier. It should not be used in pregnant women unless clearly necessary

Cefepime, pregnancy

Should not be used during pregnancy unless clearly necessary

Cefiderocol [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Fetcroja during pregnancy.

Cefixime [1], pregnancy ---> SmPC of [1] of eMC

Cefixime should not be used in pregnancy unless considered essential by the physician.

Cefotaxime [1], pregnancy ---> SmPC of [1] of eMC

Cefotaxime crosses the placental barrier. Therefore, cefotaxime should not be used during pregnancy unless the anticipated benefit outweighs any potential risks.

Cefpodoxime [1], pregnancy ---> SmPC of [1] of eMC

Cefpodoxime should be administered with caution during the early months of pregnancy.

Ceftarolin fosamil [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Zinforo during pregnancy unless the clinical condition of the woman requires treatment

Ceftazidime [1], pregnancy ---> SmPC of [1] of eMC

Ceftazidime should be prescribed to pregnant women only if the benefit outweighs the risk.

Ceftazidime/avibactam [1], pregnancy ---> SmPC of [1] of EMA

Ceftazidime/avibactam should only be used during pregnancy if the potential benefit outweighs the possible risk.

Ceftibuten, pregnancy

Ceftibuten passes the placenta and should not be used during pregnancy unless clearly necessary.

Ceftolozane/tazobactam [1], pregnancy ---> SmPC of [1] of EMA

Zerbaxa should only be used during pregnancy if the expected benefit outweighs the possible risks to the pregnant woman and foetus.

Ceftriaxone [1], pregnancy ---> SmPC of [1] of eMC

Since safety in human pregnancy is not established ceftriaxone should not be used unless absolutely indicated.

Cefuroxime axetil [1], pregnancy ---> SmPC of [1] of eMC

Cefuroxime axetil should be prescribed to pregnant women only if the benefit outweighs the risk.

Cefuroxime [1], pregnancy ---> SmPC of [1] of eMC

Cefuroxime should be prescribed to pregnant women only if the benefit outweighs the risk.

Celecoxib [1], pregnancy ---> SmPC of [1] of EMA

Celecoxib is contraindicated in pregnancy and in women who can become pregnant unless using an effective method of contraception

Celiprolol [1], pregnancy ---> SmPC of [1] of eMC

Celiprolol should not be used during pregnancy unless there is no safer alternative.

Cemiplimab [1], pregnancy ---> SmPC of [1] of EMA

Cemiplimab is not recommended during pregnancy and in women of childbearing potential not using effective contraception unless the clinical benefit outweighs the potential risk.

Cenegermin [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of OXERVATE during pregnancy.

Cenobamate [1], pregnancy ---> SmPC of [1] of EMA

Ontozry should not be used during pregnancy unless the clinical condition of the woman requires treatment with cenobamate.

Central European encephalitis virus vaccine, pregnancy

Strict indication

Cephalexin [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing for the pregnant patient.

Ceritinib [1], pregnancy ---> SmPC of [1] of EMA

Zykadia should not be used during pregnancy unless the clinical condition of the woman requires treatment with ceritinib.

Cerliponase alfa [1], pregnancy ---> SmPC of [1] of EMA

Brineura should be given to a pregnant woman only if clearly needed.

Certolizumab pegol [1], pregnancy ---> SmPC of [1] of EMA

Cimzia is not recommended during pregnancy

Certoparin, pregnancy

Should be used during pregnancy only when the possible advantages for the mother outweigh the potential risks for the foetus.

Cetirizine [1], pregnancy ---> SmPC of [1] of eMC

Cetirizine hydrochloride should not be used during pregnancy unless clearly necessary.

Cetrorelix [1], pregnancy ---> SmPC of [1] of EMA

Cetrotide is not intended to be used during pregnancy

Cetuximab [1], pregnancy ---> SmPC of [1] of EMA

It is strongly recommended that be given only during pregnancy if the potential benefit justifies a potential risk to the foetus

Cetylpyridinium [1], pregnancy ---> SmPC of [1] of eMC

Use as recommended would not be considered to constitute a hazard.

Chenodeoxycholic acid [1], pregnancy ---> SmPC of [1] of EMA

Chenodeoxycholic acid is not recommended during pregnancy and in women of childbearing potential not using contraception.

Chlomethiazole [1], pregnancy ---> SmPC of [1] of eMC

Do not use in pregnancy especially during the first and last trimesters, unless there are compelling reasons.

Chloral hydrate [1], pregnancy ---> SmPC of [1] of eMC

Chloral hydrate should not be used in pregnancy

Chlorambucil [1], pregnancy ---> SmPC of [1] of eMC

The use of chlorambucil should be avoided whenever possible during pregnancy, particularly during the first trimester.

Chloramphenicol [1], pregnancy ---> SmPC of [1] of eMC

Chloramphenicol may be absorbed systemically following the use of eye drops and may cross the placenta. Therefore this product is not recommended for use during pregnancy

Chlordiazepoxide [1], pregnancy ---> SmPC of [1] of eMC

Chlordiazepoxide should only be used during pregnancy if there are compelling reasons (e.g. no alternative: benefit outweighs risk).

Chlorhexidine [1], pregnancy ---> SmPC of [1] of eMC

Like all medicines, care should be exercised during pregnancy

Chlormadinone, pregnancy

Contraindicated

Chlormadinone/ethinylestradiol, pregnancy

It is not indicated during pregnancy

Chlormethine [1], pregnancy ---> SmPC of [1] of EMA

Ledaga is not recommended during pregnancy.

Chloroquine [1], pregnancy ---> SmPC of [1] of eMC

Chloroquine should not be used during pregnancy unless, in the judgement of the physician, potential benefit outweighs the risk.

Chlorphenamine [1], pregnancy ---> SmPC of [1] of eMC

Chlorphenamine should only be used when clearly required and when potential benefits outweigh the potential unknown risks to the foetus.

Chlorpromazine [1], pregnancy ---> SmPC of [1] of eMC

Like other drugs it should be avoided in pregnancy unless the physician considers it essential.

Chlorprothixene, pregnancy

Chlorprothixene is contraindicated in pregnancy

Chlortalidone, pregnancy

Thiazides cross the placental barrier. Contraindicated

Chlortetracycline, pregnancy

It should not be used during pregnancy

Cholecalciferol [1], pregnancy ---> SmPC of [1] of eMC

During pregnancy women should follow the advice of their physician as their requirements may vary depending on the severity of their disease and their response to treatment

Cholera vaccine (inactivated [1], oral), pregnancy ---> SmPC of [1] of EMA

Following careful benefit/risk assessment the vaccine may be administered during pregnancy

Cholera vaccine [1], pregnancy ---> SmPC of [1] of EMA

Vaxchora should be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the foetus.

Cholestyramine [1], pregnancy ---> SmPC of [1] of eMC

The safety of colestyramine in pregnancy has not been established

Cholic acid [1], pregnancy ---> SmPC of [1] of EMA

It is extremely important that pregnant women continue their therapy during pregnancy. Close monitorization.

Chondroitin sulfate, pregnancy

Contraindicated

Choriogonadotropin alfa [1], pregnancy ---> SmPC of [1] of EMA

There is no indication for the use of Ovitrelle during pregnancy.

Choriogonadotropin, pregnancy

Contraindicated

Ciclesonide [1], pregnancy ---> SmPC of [1] of eMC

As with other glucocorticoids, ciclesonide should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus.

Ciclopirox, pregnancy

Ciclopirox is not indicated during pregnancy due to the lack of clinical experience

Ciclopiroxolamine, pregnancy

Strict indication

Cidofovir [1], pregnancy ---> SmPC of [1] of EMA

Cidofovir is not recommended during pregnancy and in women of childbearing potential not using contraception.

Cilastatin, pregnancy

Strict indication

Cilazapril [1], pregnancy ---> SmPC of [1] of eMC

The use of ACE inhibitors such as cilazapril is not recommended during the first trimester of pregnancy. The use of ACE inhibitors such as cilazapril is contraindicated during the second and third trimester of pregnancy

Cilostazol [1], pregnancy ---> SmPC of [1] of EMA

Cilostazol must not be used during pregnancy

Ciltacabtagene autoleucel [1], pregnancy ---> SmPC of [1] of EMA

CARVYKTI is not recommended for women who are pregnant, or for women of childbearing potential not using contraception. Pregnant women should be advised there may be risks to the foetus.

Cimetidine [1], pregnancy ---> SmPC of [1] of eMC

Cimetidine should be avoided during pregnancy unless essential.

Cinacalcet [1], pregnancy ---> SmPC of [1] of EMA

Mimpara should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Cinchocaine, pregnancy

Strict indication

Cineole, pregnancy

Strict indication

Cinitapride, pregnancy

As a precautionary measure, it is preferable to avoid the use of cinitapride during pregnancy.

Cinnarizine [1], pregnancy ---> SmPC of [1] of eMC

It is not advisable to administer cinnarizine in pregnancy.

Cipaglucosidase alfa [1], pregnancy ---> SmPC of [1] of EMA

Animal studies with miglustat alone as well as with cipaglucosidase alfa and miglustat have shown reproductive toxicity, see section 5.3. Cipaglucosidase alfa in combination with miglustat therapy is not recommended during pregnancy.

Ciprofibrate [1], pregnancy ---> SmPC of [1] of eMC

Ciprofibrate is contraindicated during pregnancy.

Ciprofloxacin [1], pregnancy ---> SmPC of [1] of eMC

In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the drug could cause damage to articular cartilage in the human immature organism / foetus

Cisapride, pregnancy

This medicinal product should be used during pregnancy only after careful weighing of the potential benefits compared to the potential risk to the foetus, especially in the first trimester.

Cisatracurium [1], pregnancy ---> SmPC of [1] of eMC

Cisatracurium should not be used during pregnancy.

Cisplatin [1], pregnancy ---> SmPC of [1] of eMC

Cisplatin may be toxic to the foetus when administered to a pregnant woman. Cisplatin should not be used during pregnancy unless the clinician considers the risk in an individual patient to be clinically justified.

Cisplatin, pregnancy ---> SmPC of [sodium thiosulfate] of EMA

Patients receiving cisplatin are warned of the need to use appropriate contraception during treatment and for 6 months following cisplatin treatment, as cisplatin is embryotoxic and fetotoxic.

Citalopram [1], pregnancy ---> SmPC of [1] of eMC

Citalopram should not be used during pregnancy unless clearly necessary and only after careful consideration of the risk/benefit.

Citicoline, pregnancy

Strict indication

Cladribine [1], pregnancy ---> SmPC of [1] of EMA

Cladribine is contraindicated in pregnancy.

Clarithromycin [1], pregnancy ---> SmPC of [1] of eMC

Use during pregnancy is not advised without carefully weighing the benefits against risk.

Clebopride, pregnancy

Caution is recommended. In first trimester should not be administered

Clemastine [1], pregnancy ---> SmPC of [1] of eMC

Clemastine should not be given during pregnancy unless it is strictly indicated.

Clenbuterol, pregnancy

Not recommended during the pregnancy

Clindamycin [1], pregnancy ---> SmPC of [1] of eMC

Clindamycin crosses the placenta. Clindamycin should only be administered to pregnant women if the potential benefit is considered to outweigh the possible risk to the fetus.

Clobazam [1], pregnancy ---> SmPC of [1] of eMC

If it is prescribed to a woman of childbearing potential, she should be warned to contact her physician regarding discontinuation of product if she intends to become pregnant

Clobenzorex, pregnancy

Should not be used during pregnancy

Clobetasol [1], pregnancy ---> SmPC of [1] of eMC

Topical steroids should not be used extensively in pregnancy, i.e. in large amounts or for prolonged periods.

Clobetasone [1], pregnancy ---> SmPC of [1] of eMC

Administration of clobetasone during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the foetus. The minimum quantity should be used for the minimum duration.

Clocortolone, pregnancy

Contraindicated in the first trimester of pregnancy. Strict indication in the second and third

Clodronate [1], pregnancy ---> SmPC of [1] of eMC

Clodronic acid is not recommended during pregnancy and in women of childbearing potential not using effective contraception.

Clodronic acid [1], pregnancy ---> SmPC of [1] of eMC

Clodronic acid is not recommended during pregnancy and in women of childbearing potential not using effective contraception.

Clofarabine [1], pregnancy ---> SmPC of [1] of EMA

Evoltra should not be used during pregnancy, especially not during the first trimester, unless clearly necessary

Clomiphene [1], pregnancy ---> SmPC of [1] of eMC

Clomifene is not indicated during pregnancy.

Clomipramine [1], pregnancy ---> SmPC of [1] of eMC

Clomipramine is not recommended during pregnancy and in women of childbearing potential not using contraception.

Clonazepam [1], pregnancy ---> SmPC of [1] of eMC

During pregnancy, clonazepam may be administered only if there is a compelling indication.

Clonidine [1], pregnancy ---> SmPC of [1] of eMC

As with all medicines, clonidine should not be used in pregnancy, especially the first trimester, unless the expected benefit is thought to outweigh any possible risk to the foetus.

Clonixinate, pregnancy

Contraindicated

Clopamide, pregnancy

Contraindicated

Cloperastine, pregnancy

Cloperastine should not be used during the first trimester of pregnancy

Clopidogrel [1], pregnancy ---> SmPC of [1] of EMA

It is preferable not to use clopidogrel during pregnancy as a precautionary measure.

Clopidogrel/acetylsalicylic acid [1], pregnancy ---> SmPC of [1] of EMA

It should not be used during the 1st and 2nd trimester of pregnancy unless the clinical condition of the woman requires treatment. Contraindicated during the 3rd trimester.

Cloprednol, pregnancy

Strict indication

Clotrimazole [1], pregnancy ---> SmPC of [1] of eMC

Clotrimazole can be used during pregnancy, but only under the supervision of a physician or midwife.

Clozapine [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing to pregnant women.

Coagulation factor I, pregnancy

Strict indication

Coagulation factor II, pregnancy

Strict indication

Coagulation factor IIa, pregnancy

Strict indication

Coagulation factor IX [1], pregnancy ---> SmPC of [1] of EMA

Factor IX should be used during pregnancy only if clearly indicated.

Coagulation factor VIIa, pregnancy

Strict indication

Coagulation factor VIII/von Willebrand factor [1], pregnancy ---> SmPC of [1] of EMA

The coagulation factor VIII should be administered to pregnant VWF deficient women only if clearly indicated

Coagulation factor X, pregnancy

Strict indication

Coagulation factor XIII, pregnancy

Strict indication

Coagulation factor, pregnancy

Strict indication

Cobicistat [1], pregnancy ---> SmPC of [1] of EMA

Tybost should not be used during pregnancy unless the clinical condition of the woman requires treatment with cobicistat co-administered with atazanavir or darunavir.

Cobimetinib [1], pregnancy ---> SmPC of [1] of EMA

Cotellic should not be used during pregnancy unless clearly necessary and after a careful consideration of the needs of the mother and the risk to the foetus.

Codeine [1], pregnancy ---> SmPC of [1] of eMC

Risk benefit must be considered because opioid analgesics cross the placenta.

Codergocrin, pregnancy

Contraindicated

Colaspase, pregnancy

Contraindicated

Colchicine [1], pregnancy ---> SmPC of [1] of eMC

Do not use in pregnancy as there is a risk of foetal chromosome damage.

Colesevelam [1], pregnancy ---> SmPC of [1] of EMA

Caution should be exercised when prescribing to pregnant women

Colestilan [1], pregnancy ---> SmPC of [1] of EMA

No data are available to assess the safety and efficacy in pregnant women. A supplementation of vitamins may be required

Colistimethate [1], pregnancy ---> SmPC of [1] of EMA

Colistimethate sodium is not recommended during pregnancy and in women of childbearing potential not using contraception.

Colistin [1], pregnancy ---> SmPC of [1] of eMC

Colistin should only be used in pregnancy if the potential benefit justifies the potential risk.

Collagenase clostridium histolyticum [1], pregnancy ---> SmPC of [1] of EMA

The use of Xiapex is not recommended during the pregnancy and treatment should be postponed until after pregnancy.

Conestat alfa [1], pregnancy ---> SmPC of [1] of EMA

Ruconest is not recommended for use during pregnancy

Conjugated oestrogens/bazedoxifene [1], pregnancy ---> SmPC of [1] of EMA

DUAVIVE is only for use in postmenopausal women, and is contraindicated in women who are or may become pregnant

Copper chloride [1], pregnancy ---> SmPC of [1] of EMA

The use of 64 Cu-labelled medicinal products is contraindicated during established or suspected pregnancy or when pregnancy has not been excluded

Corifollitropin alfa [1], pregnancy ---> SmPC of [1] of EMA

The use during pregnancy is not indicated.

Corticorelin, pregnancy

The use of corticorelin is not recommended during pregnancy

Corticosteroids, pregnancy

Corticosteroids should not be used during pregnancy unless clearly necessary.

Cotrimoxazole [1], pregnancy ---> SmPC of [1] of eMC

Co-trimoxazole should not be used in pregnancy as the safety in pregnancy has not been established. Co-trimoxazole interferes with folate metabolism and can cause teratogenic effects if given in the first trimester.

COVID-19 mRNA vaccine [1], pregnancy ---> SmPC of [1] of EMA

Administration of Comirnaty in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.

COVID-19 vaccine [1], pregnancy ---> SmPC of [1] of EMA

Administration of Nuvaxovid in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.

Coxibs, pregnancy

Contraindicated

Crisaborole [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Staquis during pregnancy.

Crizanlizumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Adakveo during pregnancy and in woman of childbearing potential not using contraception.

Crizotinib [1], pregnancy ---> SmPC of [1] of EMA

XALKORI may cause fetal harm when administered to a pregnant woman.

Crotamiton [1], pregnancy ---> SmPC of [1] of eMC

The cream is not recommended during pregnancy, especially in the first three months.

Cyanocobalamin [1], pregnancy ---> SmPC of [1] of eMC

This medicine should not be used to treat of megaloblastic anaemia of pregnancy because this is due to folate

Cyclizine [1], pregnancy ---> SmPC of [1] of eMC

The use of cyclizine in pregnancy is not advised.

Cyclopentolate [1], pregnancy ---> SmPC of [1] of eMC

This product should not be used during pregnancy unless it is considered essential by a physician.

Cyclophosphamide [1], pregnancy ---> SmPC of [1] of eMC

This product should not normally be administered to patients who are pregnant

Cycloserine [1], pregnancy ---> SmPC of [1] of eMC

Cycloserine should be given to a pregnant woman only if clearly needed.

Cyclosporine [1], pregnancy ---> SmPC of [1] of eMC

Ciclosporin should not be used during pregnancy unless the potential benefit to the mother justifies the potential risk to the foetus.

Cyproheptadine, pregnancy

The use of this product is contraindicated during pregnancy

Cyproterone [1], pregnancy ---> SmPC of [1] of eMC

Not applicable

Cyproterone/ethinylestradiol [1], pregnancy ---> SmPC of [1] of eMC

Cyproterone/ethinylestradiol is not indicated during pregnancy.

Cysteamine [1], pregnancy ---> SmPC of [1] of EMA

Mercaptamine should not be used during pregnancy, particularly during the first trimester, unless clearly necessary.

Cytarabine [1], pregnancy ---> SmPC of [1] of EMA

Women of childbearing potential should not receive treatment until pregnancy is excluded and should be advised to use a reliable contraceptive method.

Dabigatran etexilate [1], pregnancy ---> SmPC of [1] of EMA

Pradaxa should not be used during pregnancy unless clearly necessary

Dabigatran [1], pregnancy ---> SmPC of [1] of EMA

Should not be used during pregnancy unless clearly necessary

Dabrafenib [1], pregnancy ---> SmPC of [1] of EMA

Dabrafenib should not be administered to pregnant women unless the potential benefit to the mother outweighs the possible risk to the foetus.

Dacarbazine [1], pregnancy ---> SmPC of [1] of eMC

Dacarbazine must not be used during pregnancy

Daclatasvir [1], pregnancy ---> SmPC of [1] of EMA

Daklinza should not be used during pregnancy or in women of childbearing potential not using contraception

Daclizumab [1], pregnancy ---> SmPC of [1] of EMA

Zinbryta should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Dacomitinib [1], pregnancy ---> SmPC of [1] of EMA

Based on its mechanism of action, dacomitinib may cause foetal harm when administered to a pregnant woman. Dacomitinib should not be used during pregnancy.

Dalbavancin [1], pregnancy ---> SmPC of [1] of EMA

Xydalba is not recommended during pregnancy unless clearly necessary.

Dalteparin [1], pregnancy ---> SmPC of [1] of eMC

Dalteparin can be used during pregnancy if clinically needed.

Damoctocog alfa pegol [1], pregnancy ---> SmPC of [1] of EMA

Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breast- feeding is not available. Therefore, factor VIII should be used during pregnancy and breast-feeding only if clearly indicated

Danaparoide [1], pregnancy ---> SmPC of [1] of EMA

If alternative antithrombotic treatment is unacceptable for medical reasons (e.g. HIT patients) danaparoid can be used during pregnancy.

Danazol [1], pregnancy ---> SmPC of [1] of eMC

Danazol is known to be associated with the risk of virilisation to the female foetus if administered during human pregnancy. Danazol should not be used during pregnancy.

Dantrolene [1], pregnancy ---> SmPC of [1] of eMC

Dantrolene sodium crosses the placenta. Although teratological studies in animals have proved satisfactory, the use of dantrolene is not advised in pregnant

Dapagliflozin [1], pregnancy ---> SmPC of [1] of EMA

The use of dapagliflozin is not recommended during the second and third trimesters of pregnancy

Dapagliflozin/metformin [1], pregnancy ---> SmPC of [1] of EMA

The use of this medicinal product is not recommended during the second and third trimesters of pregnancy.

Dapiprazole, pregnancy

Strict indication

Dapoxetine [1], pregnancy ---> SmPC of [1] of eMC

Dapoxetine is not indicated for women

Dapsone [1], pregnancy ---> SmPC of [1] of eMC

It is now generally considered that the benefits of dapsone in the treatment of leprosy outweigh any potential risk to the pregnant patient.

Daptomycin [1], pregnancy ---> SmPC of [1] of EMA

Cubicin should not be used during pregnancy unless clearly necessary i.e., only if the expected benefit outweighs the possible risk.

Daratumumab [1], pregnancy ---> SmPC of [1] of EMA

Daratumumab should not be used during pregnancy unless the benefit of treatment to the woman is considered to outweigh the potential risks to the fetus.

Darbepoetin alfa [1], pregnancy ---> SmPC of [1] of EMA

Caution should be exercised when prescribing to pregnant women

Daridorexant [1], pregnancy ---> SmPC of [1] of EMA

QUVIVIQ should be used during pregnancy only if the clinical condition of the pregnant woman requires treatment with daridorexant.

Darifenacin [1], pregnancy ---> SmPC of [1] of EMA

Emselex is not recommended during pregnancy.

Darolutamide [1], pregnancy ---> SmPC of [1] of EMA

Exposure of the foetus to an androgen receptor inhibitor through seminal transfer to the pregnant woman has to be avoided, as this could affect development of the foetus.

Darunavir [1], pregnancy ---> SmPC of [1] of EMA

PREZISTA co-administered with cobicistat or low dose ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk.

Darunavir/cobicistat [1], pregnancy ---> SmPC of [1] of EMA

REZOLSTA should be used during pregnancy only if the potential benefit justifies the potential risk.

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide [1], pregnancy ---> SmPC of [1] of EMA

Symtuza should be used during pregnancy only if the potential benefit justifies the potential risk.

Darunavir/ritonavir, pregnancy ---> SmPC of [darunavir] of EMA

Darunavir co-administered with cobicistat or low dose ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk.

Darvadstrocel [1], pregnancy ---> SmPC of [1] of EMA

Darvadstrocel is not recommended during pregnancy and in women of childbearing potential not using contraception.

Dasabuvir [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Exviera during pregnancy.

Dasatinib [1], pregnancy ---> SmPC of [1] of EMA

SPRYCEL should not be used during pregnancy unless the clinical condition of the woman requires treatment with dasatinib. If SPRYCEL is used during pregnancy, the patient must be informed of the potential risk to the foetus.

Daunorubicin [1], pregnancy ---> SmPC of [1] of eMC

Daunorubicin crosses the placenta. Daunorubicin should not be used during pregnancy unless the clinical condition of the woman requires treatment with daunorubicin and justifies the potential risk to the foetus.

Daunorubicin/cytarabine [1], pregnancy ---> SmPC of [1] of EMA

Based on results from animal studies and its mechanism of action, Vyxeos should not be used during pregnancy, unless the clinical condition of the woman requires treatment and justifies the potential risk to the foetus

Decitabine [1], pregnancy ---> SmPC of [1] of EMA

Dacogen should not be used during pregnancy and in women of childbearing potential not using effective contraception.

Deferasirox [1], pregnancy ---> SmPC of [1] of EMA

As a precaution, it is recommended that EXJADE is not used during pregnancy unless clearly necessary.

Deferiprone [1], pregnancy ---> SmPC of [1] of EMA

Contraindicated. Women of childbearing potential must be advised to avoid pregnancy due to the clastogenic and teratogenic properties of the medicinal product.

Deferoxamine, pregnancy

Deferoxamine may only be used during pregnancy after a careful benefit/risk assessment

Defibrotide [1], pregnancy ---> SmPC of [1] of EMA

Defitelio should not be used during pregnancy unless the clinical condition of the woman requires treatment with Defitelio.

Deflazacort [1], pregnancy ---> SmPC of [1] of eMC

Deflazacort does cross the placenta. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks.

Degarelix [1], pregnancy ---> SmPC of [1] of EMA

There is no relevant indication for use in women

Delafloxacin [1], pregnancy ---> SmPC of [1] of EMA

Delafloxacin is contraindicated during pregnancy and in women of childbearing potential not using contraception

Delamanid [1], pregnancy ---> SmPC of [1] of EMA

Deltyba is not recommended in pregnant women or in women of childbearing potential unless they are using a reliable form of contraception.

Delapril, pregnancy

The use of ACE inhibitors is not recommended during the first trimester of pregnancy. The use of ACE inhibitors is contra-indicated during the 2nd and 3rd trimester of pregnancy

Demeclocycline [1], pregnancy ---> SmPC of [1] of eMC

Demeclocycline is contra-indicated during pregnancy.

Dengue tetravalent vaccine [1], pregnancy ---> SmPC of [1] of EMA

Dengvaxia is a live attenuated vaccine, therefore Dengvaxia is contraindicated during pregnancy

Dengue tetravalent vaccine [1], pregnancy ---> SmPC of [1] of EMA

Qdenga is a live attenuated vaccine, therefore Qdenga is contraindicated during pregnancy

Denosumab [1], pregnancy ---> SmPC of [1] of EMA

XGEVA is not recommended for use in pregnant women and women of childbearing potential not using contraception.

Depreotide [1], pregnancy ---> SmPC of [1] of EMA

Depreotide is contraindicated in pregnancy

Dequalinium [1], pregnancy ---> SmPC of [1] of eMC

The safety of this product during pregnancy has not been established, but it is not considered to constitute a hazard.

Desflurane, pregnancy

There are no adequate data from the use of desflurane in pregnant women, therefore desflurane is not indicated for use during pregnancy

Desirudin [1], pregnancy ---> SmPC of [1] of EMA

Desirudin is contraindicated in pregnancy

Desloratadine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of desloratadine during pregnancy.

Desloratadine/pseudoephedrine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Aerinaze during pregnancy.

Desmopressin [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing to pregnant women.

Desogestrel [1], pregnancy ---> SmPC of [1] of eMC

Extensive epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used COCs before pregnancy, nor a teratogenic effect when COCs were taken inadvertently during early pregnancy.

Desoximetasone, pregnancy

Contraindicated

Detomidine, pregnancy

Strict indication in the first and second trimester. Contraindicated in the third trimester

Deucravacitinib [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of deucravacitinib during pregnancy.

Dexamethasone [1], pregnancy ---> SmPC of [1] of EMA

Dexamethasone is not recommended during pregnancy unless the potential benefit justifies the potential risk to the foetus.

Dexchlorpheniramine, pregnancy

Strict indication in the first and second trimester. Contraindicated in the third trimester

Dexibuprofen [1], pregnancy ---> SmPC of [1] of eMC

Like other drugs of this class, dexibuprofen should only be administered in the first 5 months of pregnancy if clearly needed. From the beginning of the 6th month of pregnancy onward dexibuprofen is contraindicated.

Dexketoprofen [1], pregnancy ---> SmPC of [1] of eMC

During the first and second trimester of pregnancy, dexketoprofen trometamol should not be given unless clearly necessary. During the thirds trimester of pregnancy is contraindicated

Dexmedetomidine [1], pregnancy ---> SmPC of [1] of EMA

Dexdor is not recommended during pregnancy and in women of childbearing potential not using contraception.

Dexrazoxane [1], pregnancy ---> SmPC of [1] of EMA

Dexrazoxane should not be used during pregnancy unless clearly necessary

Dextromethorphan [1], pregnancy ---> SmPC of [1] of eMC

It should only be used when the potential benefit of treatment to the mother exceeds any possible hazards to the developing foetus

Dextromethorphan/quinidine [1], pregnancy ---> SmPC of [1] of EMA

As this medicinal product may cause foetal harm, it is not recommended during pregnancy and in women of childbearing potential not using contraception.

Dextropropoxyphene, pregnancy

Dextropropoxyphene should be avoided during pregnancy unless essential.

Diacerein, pregnancy

Diacerein is contraindicated in pregnancy

Diamorphine [1], pregnancy ---> SmPC of [1] of eMC

Safety has not been established in pregnancy.

Diazepam [1], pregnancy ---> SmPC of [1] of eMC

If diazepam is prescribed to a woman of childbearing potential, she should be warned to contact her physician regarding discontinuance of diazepam if she intends to become, or suspects that she is pregnant.

Diazoxide, pregnancy

Diazoxide should not be administered to pregnant women or to women with child-bearing potential except in life-threatening situations

Dibotermin alfa [1], pregnancy ---> SmPC of [1] of EMA

Dibotermin alfa should not be used during pregnancy unless clearly necessary

Diclofenac [1], pregnancy ---> SmPC of [1] of eMC

NSAIDs should not be used during the first two trimesters of pregnancy or labour unless the potential benefit to the patient outweighs the potential risk to the foetus. The use in the last trimester of pregnancy is contraindicated.

Dicycloverine [1], pregnancy ---> SmPC of [1] of eMC

The drug should be used during pregnancy only if clearly needed.

Didanosine [1], pregnancy ---> SmPC of [1] of eMC

The use of didanosine during pregnancy should be considered only if clearly indicated, and only when the potential benefit outweighs the possible risk.

Dienogest, pregnancy

Dienogest should not be given to pregnant women due to it is not necessary to treat a endometriosis during pregnancy

Difelikefalin [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Kapruvia during pregnancy.

Diflorasone, pregnancy

Contraindicated

Digitoxin, pregnancy

The pregnant woman should be carefully monitored during the pregnancy

Digoxin [1], pregnancy ---> SmPC of [1] of eMC

As with all drugs, use should be considered only when the expected clinical benefit of treatment to the mother outweighs any possible risk to the developing foetus.

Dihexazin, pregnancy

Contraindicated

Dihydralazine, pregnancy

Contraindicated in the first trimester. Strict indication in the second and third

Dihydroartemisinin, pregnancy

Not recommended during the pregnancy

Dihydrocodeine [1], pregnancy ---> SmPC of [1] of eMC

A possible association with respiratory and cardiac malformations has been reported following first trimester exposure to codeine. Dihydrocodeine may cause respiratory depression in the neonate.

Dihydroergotamine, pregnancy

Dihydroergotamine is contraindicated during the whole pregnancy

Dihydroergotoxine, pregnancy

Contraindicated

Dihydropyridines, pregnancy

Dihydropyridines have the potential to prolong the period of expulsion and the delivery

Dihydrotachysterol [1], pregnancy ---> SmPC of [1] of eMC

Treatment is only justified if potential benefits outweigh possible risks.

Diisopropylamine, pregnancy

Avoid long-term treatment on large surfaces

Diloxanide [1], pregnancy ---> SmPC of [1] of eMC

It use should be avoided during the pregnancy

Diltiazem [1], pregnancy ---> SmPC of [1] of eMC

Diltiazem is not recommended during pregnancy, as well as in women of child-bearing potential not using effective contraception.

Dimenhydrinate, pregnancy

Strict indication in the 1st and 2nd trimester. Contraindicated in the last weeks of pregnancy

Dimercaptopropanoyl sulfonic acid, pregnancy

Strict indication

Dimethindene, pregnancy

Strict indication

Dimethyl fumarate [1], pregnancy ---> SmPC of [1] of EMA

Tecfidera should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the foetus.

Dinoprostone [1], pregnancy ---> SmPC of [1] of eMC

The product is for the initiation of cervical ripening in pregnant patients at term only where labour induction is indicated. It is not indicated for use during early or other phases of pregnancy

Dinutuximab [1], pregnancy ---> SmPC of [1] of EMA

It is recommended that women of childbearing potential use contraception for 6 months after discontinuation of treatment with Unituxin.

Diosmin, pregnancy

Caution is warranted when prescribing diosmin to pregnant women

Diphenhydramine [1], pregnancy ---> SmPC of [1] of eMC

Diphenhydramine crosses the placental barrier. This drug is not recommended during pregnancy.

Dipivefrine, pregnancy

Should not be used during pregnancy unless clearly needed

Dipotassium clorazepate, pregnancy

Strict indication

Dipyridamole [1], pregnancy ---> SmPC of [1] of eMC

Medicines should not be used in pregnancy, especially the first trimester unless the expected benefit is thought to outweigh the possible risk to the foetus

Diroximel fumarate [1], pregnancy ---> SmPC of [1] of EMA

Vumerity should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the foetus.

Disodium folinate, pregnancy

Contraindicated

Disopyramide [1], pregnancy ---> SmPC of [1] of eMC

The drug should only be used during pregnancy if benefits clearly outweigh the possible risks to the mother and foetus.

Distigmine, pregnancy

Distigmine should not be used in pregnancy, especially during the first trimester.

Disulfiram [1], pregnancy ---> SmPC of [1] of eMC

The use of disulfiram in the 1st trimester of pregnancy is not advised. The risk/benefit ratio in assessing adverse effects of alcoholism in pregnancy should be taken into account when considering the use of disulfiram in pregnant patients

Dithranol, pregnancy

The cream may be applied, when the necessity is evident

Dixyrazine, pregnancy

The neuroleptic passes the placenta

Docetaxel [1], pregnancy ---> SmPC of [1] of EMA

Docetaxel must not be used during pregnancy unless clearly indicated.

Docosanol [1], pregnancy ---> SmPC of [1] of eMC

Since systemic exposure to docosanol is negligible, docosanol can be used during pregnancy.

Dofetilide [1], pregnancy ---> SmPC of [1] of EMA

Should not be used in pregnant women unless clearly necessary

Dolasetron, pregnancy

Should not be used in pregnant women unless clearly necessary

Dolutegravir [1], pregnancy ---> SmPC of [1] of EMA

Dolutegravir should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.

Dolutegravir/abacavir/lamivudine [1], pregnancy ---> SmPC of [1] of EMA

Triumeq should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.

Dolutegravir/lamivudine [1], pregnancy ---> SmPC of [1] of EMA

Dovato should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.

Dolutegravir/rilpivirine [1], pregnancy ---> SmPC of [1] of EMA

Lower exposures of dolutegravir or rilpivirine were observed when taken once daily, in combination with a background regimen, during pregnancy. Therefore, use of Juluca during pregnancy is not recommended

Domperidone [1], pregnancy ---> SmPC of [1] of eMC

Domperidone should only be used during pregnancy when justified by the anticipated therapeutic benefit.

Donepezil [1], pregnancy ---> SmPC of [1] of eMC

Donepezil should not be used during pregnancy unless clearly necessary.

Dopamine [1], pregnancy ---> SmPC of [1] of eMC

The drug should be used in pregnant women only when the expected benefits outweigh the potential risk to the foetus.

Doravirine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of doravirine during pregnancy.

Doravirine/lamivudine/tenofovir disoproxil [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Delstrigo during pregnancy.

Doripenem [1], pregnancy ---> SmPC of [1] of EMA

Doripenem should not be used during pregnancy unless clearly necessary.

Dornase alfa [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing dornase alfa to pregnant women.

Dorzolamide [1], pregnancy ---> SmPC of [1] of eMC

Should not be used during pregnancy. In rabbits, dorzolamide produced teratogenic effect at maternotoxic doses

Dorzolamide/timolol [1], pregnancy ---> SmPC of [1] of eMC

It should not be used during pregnancy.

Dostarlimab [1], pregnancy ---> SmPC of [1] of EMA

JEMPERLI is not recommended during pregnancy and in women of childbearing potential not using contraception.

Doubutamine [1], pregnancy ---> SmPC of [1] of eMC

There are no adequate studies in human pregnancy and therefore dobutamine should not be used without very careful consideration of the balance of risk.

Doxapram [1], pregnancy ---> SmPC of [1] of eMC

This product is not recommended for use in pregnancy unless there are compelling clinical reasons to do so. The physician must weigh the benefit to the risk.

Doxazosin [1], pregnancy ---> SmPC of [1] of eMC

Doxazosin should be used during pregnancy only if the potential benefit outweighs the risk.

Doxepin [1], pregnancy ---> SmPC of [1] of eMC

Doxepin crosses the placenta. Since there is insufficient experience in pregnant women who have received this drug, its safety in pregnancy has not been established.

Doxofylline, pregnancy

Contraindicated

Doxorubicine [1], pregnancy ---> SmPC of [1] of eMC

Doxorubicin should not be given during pregnancy. In general cytostatics should only be administered during pregnancy on strict indication, and the benefit to the mother weighed against possible hazards to the foetus.

Doxycycline [1], pregnancy ---> SmPC of [1] of eMC

Doxycycline is contra-indicated in pregnancy. It appears that the risks associated with the use of tetracyclines during pregnancy are predominantly due to effects on teeth and skeletal development.

Doxylamine, pregnancy

Doxylamine is contraindicated during pregnancy

Dronedarone [1], pregnancy ---> SmPC of [1] of EMA

MULTAQ is not recommended during pregnancy and in women of childbearing potential not using contraception.

Droperidol [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure, it is preferable not to administer droperidol during pregnancy. In late pregnancy, if its administration is necessary, monitoring of the newborn's neurological functions is recommended.

Dropropizine, pregnancy

Strict indication

Drospirenone, pregnancy

Contraindicated

Drospirenone/estetrol [1], pregnancy ---> SmPC of [1] of EMA

Drovelis is not indicated during pregnancy. If pregnancy occurs while taking Drovelis, further intake must be stopped.

Drotrecogin alfa [1], pregnancy ---> SmPC of [1] of EMA

Should not be used during pregnancy unless clearly necessary

Drugs that act directly on the renin-angiotensin-aldosterone system, pregnancy

Drugs that act directly on the renin-angiotensin-aldosterone system can have harmful pharmacological effects on pregnancy and the fetus/new-born child (including death)

Dulaglutide [1], pregnancy ---> SmPC of [1] of EMA

The use of dulaglutide is not recommended during pregnancy.

Duloxetine [1], pregnancy ---> SmPC of [1] of EMA

YENTREVE should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus. Women should be advised to notify their physician if they become pregnant, or intend to become pregnant, during therapy.

Dupilumab [1], pregnancy ---> SmPC of [1] of EMA

Dupixent should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Durvalumab [1], pregnancy ---> SmPC of [1] of EMA

Durvalumab may cause foetal harm when administered to a pregnant woman and is not recommended during pregnancy and in women of childbearing potential not using effective contraception during treatment and for at least 3 months after the last dose.

Dutasteride [1], pregnancy ---> SmPC of [1] of eMC

If administered to a woman carrying a male foetus, inhibit the development of the external genitalia of the foetus. Dutasteride is contraindicated for use by women.

Duvelisib [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Copiktra during pregnancy.

Dydrogesterone, pregnancy

Dydrogesterone is not approved for use during pregnancy.

Dydrogesterone/estradiol [1], pregnancy ---> SmPC of [1] of eMC

Dydrogesterone/estradiol is not indicated during pregnancy.

Ebastine, pregnancy

Ebastine should be used during pregnancy only when clearly needed

Ebola vaccine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid vaccination with Mvabea during pregnancy.

Ebola Zaire vaccine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Ervebo during pregnancy. Nevertheless considering the severity of EVD, vaccination should not be withheld when there is a clear risk of exposure to Ebola infection.

Econazole [1], pregnancy ---> SmPC of [1] of eMC

Econazole should be used in pregnancy only if the practitioner considers it to be necessary.

Eculizumab [1], pregnancy ---> SmPC of [1] of EMA

Soliris should be given to a pregnant woman only if clearly needed.

Edotreotide [1], pregnancy ---> SmPC of [1] of EMA

Only essential investigations should therefore be carried out during pregnancy, when the likely benefit far exceeds the risk incurred by the mother and foetus.

Edoxaban [1], pregnancy ---> SmPC of [1] of EMA

Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that edoxaban passes the placenta, Lixiana is contraindicated during pregnancy.

Edrophonium [1], pregnancy ---> SmPC of [1] of eMC

The safety during pregnancy has not been established.

Efalizumab [1], pregnancy ---> SmPC of [1] of EMA

Should not be used during pregnancy

Efavirenz [1], pregnancy ---> SmPC of [1] of EMA

Efavirenz should not be used during pregnancy, unless the patient's clinical condition requires such treatment

Efgartigimod alfa [1], pregnancy ---> SmPC of [1] of EMA

Treatment of pregnant women with Vyvgart should only be considered if the clinical benefit outweighs the risks.

Eflornithine [1], pregnancy ---> SmPC of [1] of EMA

Women who are pregnant or planning pregnancy should use an alternative means to manage facial hair.

Efmoroctocog alfa [1], pregnancy ---> SmPC of [1] of EMA

Factor VIII should be used during pregnancy and lactation only if clearly indicated.

Eftrenonacog alfa [1], pregnancy ---> SmPC of [1] of EMA

Based on the rare occurrence of haemophilia B in women, experience regarding the use of factor IX during pregnancy and breast-feeding is not available. Therefore, factor IX should be used during pregnancy and breast-feeding only if clearly indicated.

Eladocagene exuparvovec [1], pregnancy ---> SmPC of [1] of EMA

There are no data from the use of eladocagene exuparvovec in pregnant women.

Elbasvir/grazoprevir [1], pregnancy ---> SmPC of [1] of EMA

Because reproduction animal studies are not always predictive of human response, ZEPATIER should be used only if the potential benefit justifies the potential risk to the fetus.

Elcatonin, pregnancy

Elcatonin should be used during pregnancy only if treatment is considered absolutely essential by the physician.

Eletriptan [1], pregnancy ---> SmPC of [1] of eMC

Eletriptan should be used during pregnancy only if clearly needed.

Eliglustat [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is recommended to avoid the use of Cerdelga during pregnancy.

Elosulfase alfa [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of elosulfase alfa during pregnancy, unless clearly necessary.

Elotuzumab [1], pregnancy ---> SmPC of [1] of EMA

Empliciti should not be used during pregnancy unless the clinical condition of the woman requires treatment with elotuzumab.

Eltrombopag [1], pregnancy ---> SmPC of [1] of EMA

Revolade is not recommended during pregnancy.

Eluxadoline [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Truberzi during pregnancy.

Elvitegravir [1], pregnancy ---> SmPC of [1] of EMA

Vitekta should not be used during pregnancy unless the clinical condition of the woman requires treatment with elvitegravir.

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [1], pregnancy ---> SmPC of [1] of EMA

Genvoya should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil [1], pregnancy ---> SmPC of [1] of EMA

Stribild should be used during pregnancy only if the potential benefit justifies the potential risk.

Emedastine [1], pregnancy ---> SmPC of [1] of EMA

Emedastine can be used during pregnancy if the dosage recommendation is respected.

Emicizumab [1], pregnancy ---> SmPC of [1] of EMA

Hemlibra should be used during pregnancy only if the potential benefit for the mother outweighs the potential risk to the fetus

Empagliflozin [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Jardiance during pregnancy.

Empagliflozin/linagliptin [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure it is preferable to avoid the use of Glyxambi during pregnancy.

Empagliflozin/metformin [1], pregnancy ---> SmPC of [1] of EMA

When the patient plans to become pregnant, and during pregnancy, it is recommended that diabetes is not treated with this medicinal product, but insulin be used to maintain blood glucose levels as close to normal as possible

Emtricitabine [1], pregnancy ---> SmPC of [1] of EMA

The use of emtricitabine may be considered during pregnancy, if necessary.

Emtricitabine/rilpivirine/tenofovir alafenamide [1], pregnancy ---> SmPC of [1] of EMA

Odefsey should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Emtricitabine/rilpivirine/tenofovir disoproxil [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Eviplera during pregnancy.

Emtricitabine/tenofovir alafenamide [1], pregnancy ---> SmPC of [1] of EMA

Descovy should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Emtricitabine/tenofovir disoproxil [1], pregnancy ---> SmPC of [1] of EMA

The use of Truvada may be considered during pregnancy, if necessary.

Enalapril [1], pregnancy ---> SmPC of [1] of eMC

The use of ACE inhibitors is not recommended during the 1st trimester of pregnancy and are contraindicated during the 2nd and 3rd trimester of pregnancy.

Enalapril/hydrochlorothiazide [1], pregnancy ---> SmPC of [1] of eMC

The use of ACE inhibitors is not recommended during the first trimester of pregnancy. The use of ACE inhibitors is contra-indicated during the second and third trimester of pregnancy

Encephalitis vaccine, pregnancy

As a precautionary measure, during pregnancy should be avoided

Encorafenib [1], pregnancy ---> SmPC of [1] of EMA

Encorafenib is not recommended during pregnancy and in women of childbearing potential not using contraception.

Enflurane, pregnancy

Should not be used in pregnant women unless clearly necessary

Enfortumab vedotin [1], pregnancy ---> SmPC of [1] of EMA

Padcev is not recommended during pregnancy and in women of childbearing potential not using effective contraception.

Enfuvirtide [1], pregnancy ---> SmPC of [1] of EMA

Enfuvirtide should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Enoxacin, pregnancy

Contraindicated

Enoxaparin sodium [1], pregnancy ---> SmPC of [1] of EMA

This medicinal product should be used during pregnancy only if the physician has established a clear need.

Enoxaparin [1], pregnancy ---> SmPC of [1] of eMC

This drug should be used during pregnancy only if the physician has established a clear need.

Enoximone, pregnancy

Enoximone is contraindicated during pregnancy

Entacapone [1], pregnancy ---> SmPC of [1] of EMA

As there is no experience in pregnant women, entacapone should not be used during pregnancy.

Entecavir [1], pregnancy ---> SmPC of [1] of EMA

Baraclude should not be used during pregnancy unless clearly necessary.

Entrectinib [1], pregnancy ---> SmPC of [1] of EMA

Rozlytrek is not recommended during pregnancy and in women of childbearing potential not using contraception. Female patients receiving Rozlytrek should be advised of the potential harm to the foetus

Enzalutamide [1], pregnancy ---> SmPC of [1] of EMA

Enzalutamide is not for use in women. Enzalutamide is contraindicated in women who are or may become pregnant

Ephedrine [1], pregnancy ---> SmPC of [1] of eMC

Ephedrine should be avoided or used with caution, and only if necessary, during pregnancy.

Epinastine [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing to pregnant women.

Epinephrine [1], pregnancy ---> SmPC of [1] of eMC

Adrenaline should only be used in pregnancy if the potential benefits outweigh the risks to the foetus.

Epirubicin [1], pregnancy ---> SmPC of [1] of eMC

Epirubicin should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.

Eplerenone [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised prescribing eplerenone to pregnant women.

Epoetin alfa [1], pregnancy ---> SmPC of [1] of EMA

There are no or limited amount of data from the use of epoetin alfa in pregnant women.

Epoetin beta [1], pregnancy ---> SmPC of [1] of EMA

Caution should be exercised when prescribing to pregnant women.

Epoetin delta, pregnancy

Caution should be exercised when prescribing to pregnant women

Epoetin theta [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Eporatio during pregnancy.

Epoetin zeta [1], pregnancy ---> SmPC of [1] of EMA

Erythropoietin should be used during pregnancy only if the potential benefit outweighs the potential risk to the foetus.

Epoprostenol [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure, it is preferable to avoid the use of epoprostenol during pregnancy.

Eprosartan [1], pregnancy ---> SmPC of [1] of eMC

The use of eprosartan is not recommended during the first trimester of pregnancy. The use of eprosartan is contraindicated during second and third trimester of pregnancy

Eptacog alfa (activated) [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid use of NovoSeven during pregnancy.

Eptacog beta [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of this medicinal product during pregnancy.

Eptifibatide [1], pregnancy ---> SmPC of [1] of EMA

INTEGRILIN should not be used during pregnancy unless clearly necessary

Eptinezumab [1], pregnancy ---> SmPC of [1] of EMA

Human IgG is known to cross the placental barrier; therefore, eptinezumab may be transmitted from the mother to the developing fetus. As a precautionary measure, it is preferable to avoid the use of VYEPTI during pregnancy.

Eptotermin alfa [1], pregnancy ---> SmPC of [1] of EMA

The medicinal product should not be used during pregnancy unless the potential benefit justifies the potential risks to the foetus

Eravacycline [1], pregnancy ---> SmPC of [1] of EMA

Xerava should not be used during pregnancy unless the clinical condition of the woman requires treatment with eravacycline.

Erenumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Aimovig during pregnancy.

Ergometrine [1], pregnancy ---> SmPC of [1] of eMC

The use of ergometrine is entirely restricted to the third stage of labour, otherwise it is not recommended for use during pregnancy and lactation.

Ergot derivatives, pregnancy

Contraindicated

Ergotamine, pregnancy

Ergotamine is contraindicated during the whole pregnancy

Eribulin [1], pregnancy ---> SmPC of [1] of EMA

HALAVEN should not be used during pregnancy unless clearly necessary and after a careful consideration of the needs of the mother and the risk to the foetus.

Erlotinib [1], pregnancy ---> SmPC of [1] of EMA

An adverse effect on the pregnancy can not be excluded as rat and rabbit studies have shown increased embryo/foetal lethality. The potential risk for humans is unknown.

Ertapenem [1], pregnancy ---> SmPC of [1] of EMA

Ertapenem should not be used during pregnancy unless the potential benefit outweighs the possible risk to the foetus

Ertugliflozin [1], pregnancy ---> SmPC of [1] of EMA

Based on results from animal studies, ertugliflozin may affect renal development and maturation. Therefore, Steglatro should not be used during pregnancy.

Ertugliflozin/metformin [1], pregnancy ---> SmPC of [1] of EMA

There are limited data from the use of ertugliflozin in pregnant women. Based on results from animal studies, ertugliflozin may affect renal development and maturation. Therefore, Segluromet should not be used during pregnancy.

Erythromycin [1], pregnancy ---> SmPC of [1] of eMC

Like all drugs erythromycin should be used in pregnancy only when clearly indicated. Erythromycin crosses the placental barrier.

Erythropoietin, pregnancy

Erythropoietin should be used during pregnancy only if the potential benefit outweighs the potential risk to the foetus.

Escin, pregnancy

Contraindicated

Escitalopram [1], pregnancy ---> SmPC of [1] of eMC

Escitalopram should not be used during pregnancy unless clearly necessary and only after careful consideration of the risk/benefit.

Eserine, pregnancy

Should not be used during pregnancy unless clearly needed

Esketamine [1], pregnancy ---> SmPC of [1] of EMA

If a woman becomes pregnant while being treated with Spravato, treatment should be discontinued, and the patient should be counselled about the potential risk to the foetus and clinical/therapeutic options as soon as possible.

Esketamine, pregnancy

Esketamine should not be used during pregnancy and only when the possible advantages for the mother outweigh the potential risks for the foetus.

Eslicarbazepine [1], pregnancy ---> SmPC of [1] of EMA

Patients should be counselled regarding the possibility of an increased risk of malformations and given the opportunity to antenatal screening.

Esmolol [1], pregnancy ---> SmPC of [1] of eMC

Esmolol is not recommended during pregnancy.

Esomeprazole [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Nexium Control during pregnancy.

Estradiol valerate/norgestrel [1], pregnancy ---> SmPC of [1] of eMC

This medicinal product is not indicated during pregnancy.

Estradiol [1], pregnancy ---> SmPC of [1] of eMC

This medicinal product is not indicated during pregnancy. If pregnancy occurs during medication, treatment should be withdrawn immediately.

Estradiol/norethisterone [1], pregnancy ---> SmPC of [1] of eMC

Estradiol/norethisterone is not indicated during pregnancy.

Estramustine [1], pregnancy ---> SmPC of [1] of eMC

Estramustine is not indicated for women.

Estriol [1], pregnancy ---> SmPC of [1] of eMC

Estriol is not indicated during pregnancy. If pregnancy occurs during medication with Estriol treatment should be withdrawn immediately.

Estrogens, pregnancy

It is not indicated during pregnancy.

Etamsylate, pregnancy

Contraindicated in the first trimester. Strict indication in the second and third trimester

Etanercept [1], pregnancy ---> SmPC of [1] of EMA

Enbrel is not recommended during pregnancy.

Etelcalcetide [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Parsabiv during pregnancy.

Ethacridine, pregnancy

Strict indication

Ethambutol [1], pregnancy ---> SmPC of [1] of eMC

Ethambutol should not be used in pregnant women or women of childbearing potential unless the potential benefit to the mother is considered to outweigh any possible risk to the foetus.

Ethinyl estradiol [1], pregnancy ---> SmPC of [1] of eMC

Ethinylestradiol is not indicated during pregnancy.

Ethinylestradiol/chlormadinone, pregnancy

It should not be used during pregnancy

Ethinylestradiol/desogestrel [1], pregnancy ---> SmPC of [1] of eMC

Combined oral contraceptives are not indicated for use during pregnancy.

Ethinylestradiol/drospirenone [1], pregnancy ---> SmPC of [1] of eMC

Ethinylestradiol/drospirenone is not indicated during pregnancy.

Ethinylestradiol/etonogestrel [1], pregnancy ---> SmPC of [1] of eMC

It is not indicated during pregnancy.

Ethinylestradiol/gestodene [1], pregnancy ---> SmPC of [1] of eMC

Ethinylestradiol/gestodene is not indicated during pregnancy.

Ethinylestradiol/norgestimate [1], pregnancy ---> SmPC of [1] of eMC

Not indicated during pregnancy.

Ethosuximide [1], pregnancy ---> SmPC of [1] of eMC

There is a recognised small increase in the incidence of congenital malformations in children born to mothers receiving anticonvulsants. For women planning pregnancy or who are already pregnant the risk should be weighed carefully

Ethyl chloride, pregnancy

Strict indication

Ethyl loflazepate, pregnancy

The benzodiazepine crosses the placental barrier. Contraindicated

Ethynodiol, pregnancy

Contraindicated

Etidronate [1], pregnancy ---> SmPC of [1] of eMC

It is recommended that etidronate should not be used in women of childbearing potential unless adequate contraceptive measures are taken.

Etidronic acid [1], pregnancy ---> SmPC of [1] of eMC

It is recommended that etidronate should not be used in women of childbearing potential unless adequate contraceptive measures are taken.

Etilefrine, pregnancy

Contraindicated in the 1st trimester. Strict indication in the 2nd and 3rd trimester

Etofamide, pregnancy

Contraindicated in the first trimester

Etofenamate, pregnancy

It should not be used during pregnancy unless clearly needed

Etomidate [1], pregnancy ---> SmPC of [1] of eMC

As with other drugs, the possible risks should be weighed against the potential benefits before the drug is administered during pregnancy.

Etonogestrel [1], pregnancy ---> SmPC of [1] of eMC

The implant is not indicated during pregnancy. If pregnancy occurs during use, the implant should be removed.

Etoposide [1], pregnancy ---> SmPC of [1] of eMC

Etoposide can cause foetal harm when administered to pregnant women. If it is used during pregnancy, or if the patient becomes pregnant while receiving this product, the patient should be appraised of the potential hazard to the foetus.

Etoricoxib [1], pregnancy ---> SmPC of [1] of eMC

Etoricoxib is contraindicated in pregnancy. If a woman becomes pregnant during treatment, etoricoxib must be discontinued.

Etranacogene dezaparvovec [1], pregnancy ---> SmPC of [1] of EMA

It is not known whether this medicinal product can cause foetal harm when administered to a pregnant woman or can affect reproductive capacity. Hemgenix should not be used during pregnancy.

Etravirine [1], pregnancy ---> SmPC of [1] of EMA

Based on limited data available, no dose adjustment is required during pregnancy and postpartum

Everolimus [1], pregnancy ---> SmPC of [1] of EMA

Everolimus is not recommended during pregnancy and in women of childbearing potential not using contraception.

Evolocumab [1], pregnancy ---> SmPC of [1] of EMA

Repatha should not be used during pregnancy unless the clinical condition of the woman requires treatment with evolocumab.

Ex vivo expanded autologous human corneal epithelial cells [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, and in light of the requirement of the post-operative pharmacological treatment, it is preferable to avoid the use of Holoclar during pregnancy.

Exemestane [1], pregnancy ---> SmPC of [1] of eMC

Exemestane is contraindicated in pregnant women.

Exenatide [1], pregnancy ---> SmPC of [1] of EMA

Prolonged-release exenatide should not be used during pregnancy and the use of insulin is recommended. Prolonged-release exenatide should be discontinued at least 3 months before a planned pregnancy.

Extract from birch bark [1], pregnancy ---> SmPC of [1] of EMA

Episalvan can be used during pregnancy.

Ezetimibe [1], pregnancy ---> SmPC of [1] of eMC

Ezetimibe should be given to pregnant women only if clearly necessary. Ezetimibe co-administered with a statin is contraindicated during pregnancy

Ezetimibe/atorvastatin [1], pregnancy ---> SmPC of [1] of eMC

ATOZET is contraindicated during pregnancy

Ezetimibe/simvastatine [1], pregnancy ---> SmPC of [1] of eMC

This medicinal product is contraindicated during pregnancy.

Famciclovir [1], pregnancy ---> SmPC of [1] of eMC

Famciclovir should only be used during pregnancy when the potential benefits of treatment outweigh the potential risks.

Famotidine, pregnancy

Famotidine is not recommended during the pregnancy

Fampridine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure it is preferable to avoid the use of Fampyra in pregnancy.

Faricimab [1], pregnancy ---> SmPC of [1] of EMA

Faricimab should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.

Febuxostat [1], pregnancy ---> SmPC of [1] of EMA

Febuxostat should not be used during pregnancy.

Fedratinib [1], pregnancy ---> SmPC of [1] of EMA

Inrebic is contraindicated during pregnancy. Women of childbearing potential have to use effective contraception during treatment and for at least 1 month after the last dose.

Felbamate, pregnancy

Felbamate passes the placenta and should not be used during pregnancy

Felodipine [1], pregnancy ---> SmPC of [1] of eMC

Felodipine should not be given during pregnancy.

Felodipine/metoprolol, pregnancy

Felodipine/metoprolol should not be used during pregnancy

Felodipine/ramipril [1], pregnancy ---> SmPC of [1] of eMC

The product is contra-indicated in pregnancy.

Fenfluramine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Fintepla during pregnancy.

Fenofibrate [1], pregnancy ---> SmPC of [1] of eMC

Fenofibrate should only be used during pregnancy after a careful benefit/risk assessment.

Fenofibrate/simvastatin [1], pregnancy ---> SmPC of [1] of EMA

Simvastatin is contraindicated during pregnancy.

Fenoterol, pregnancy

Strict indication

Fenproporex, pregnancy

Contraindicated

Fentanyl [1], pregnancy ---> SmPC of [1] of EMA

Effentora should not be used during pregnancy unless clearly necessary

Fenticonazole [1], pregnancy ---> SmPC of [1] of eMC

Since there is no experience of use during pregnancy or lactation, fenticonazole should not be used unless the physician considers it essential to the welfare of the patient.

Ferric citrate coordination complex [1], pregnancy ---> SmPC of [1] of EMA

Fexeric is not recommended during pregnancy and in women of childbearing potential not using contraceptive methods.

Ferric maltol [1], pregnancy ---> SmPC of [1] of EMA

As precautionary measure, it is preferable to avoid the use of Feraccru during pregnancy.

Ferucarbotran, pregnancy

Should not be used in pregnant women unless clearly necessary

Ferumoxsil, pregnancy

Should not be used during pregnancy

Ferumoxytol [1], pregnancy ---> SmPC of [1] of EMA

A careful risk/benefit evaluation is therefore required before use during pregnancy and Rienso should not be used during pregnancy unless clearly necessary

Fesoterodine [1], pregnancy ---> SmPC of [1] of EMA

TOVIAZ is not recommended during pregnancy.

Fexofenadine [1], pregnancy ---> SmPC of [1] of eMC

Fexofenadine hydrochloride should not be used during pregnancy unless clearly necessary.

Fibrinogen, pregnancy

Strict indication

Fidaxomicin [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of DIFICLIR during pregnancy.

Filgotinib [1], pregnancy ---> SmPC of [1] of EMA

Based on findings in animals, filgotinib may cause foetal harm and is therefore contraindicated during pregnancy

Filgrastim [1], pregnancy ---> SmPC of [1] of EMA

Filgrastim is not recommended during pregnancy.

Finasteride [1], pregnancy ---> SmPC of [1] of eMC

Finasteride is contraindicated for use in women when they are or may potentially be pregnant

Finerenone [1], pregnancy ---> SmPC of [1] of EMA

If a woman becomes pregnant while taking finerenone, she should be informed of potential risks to the foetus. Women of childbearing potential should be advised to use effective contraception during treatment with finerenone.

Fingolimod [1], pregnancy ---> SmPC of [1] of EMA

While on treatment, women should not become pregnant and active contraception is recommended.

Flavoxate [1], pregnancy ---> SmPC of [1] of eMC

Flavoxate should be avoided in pregnancy unless there is no safer alternative.

Flecainide [1], pregnancy ---> SmPC of [1] of eMC

Flecainide should only be used in pregnancy if the benefit outweighs the risks.

Florbetaben [1], pregnancy ---> SmPC of [1] of EMA

Radionuclide procedures carried out on pregnant women also involve radiation dose to the foetus. Only essential investigations should therefore be carried out during pregnancy, when the likely benefit far exceeds the risk incurred by the mother and foetu

Florbetapir [1], pregnancy ---> SmPC of [1] of EMA

Only essential investigations should be carried out during pregnancy, when the likely benefit far exceeds the risk incurred by the mother and foetus

Fluciclovine (18F) [1], pregnancy ---> SmPC of [1] of EMA

Fluciclovine (18F) is not indicated for use in women

Flucloxacillin [1], pregnancy ---> SmPC of [1] of eMC

Flucloxacillin should only be used in pregnancy when the potential benefits outweigh the risks associated with treatment.

Fluconazole [1], pregnancy ---> SmPC of [1] of eMC

Fluconazole in standard doses and short-term treatments should not be used in pregnancy unless clearly necessary.

Flucytosine [1], pregnancy ---> SmPC of [1] of eMC

The use of flucytosine in pregnancy and in women of childbearing age requires that the potential benefits of therapy be weighed against its possible hazards.

Fludarabine [1], pregnancy ---> SmPC of [1] of eMC

Fludarabine should not be used during pregnancy unless clearly necessary

Fludrocortisone [1], pregnancy ---> SmPC of [1] of eMC

It may be decided to continue a pregnancy in a woman requiring replacement mineralocorticoid therapy, despite the risk to the foetus.

Flufenamic acid, pregnancy

Contraindicated

Flumazenil [1], pregnancy ---> SmPC of [1] of eMC

Like other benzodiazepine compounds, Flumazenil Injection is expected to cross the placenta.

Flumetasone, pregnancy

Application of the cream is contraindicated during pregnancy

Flunarizine, pregnancy

As a precautionary measure, it is preferable to avoid the use of flunarizine during pregnancy.

Flunisolide, pregnancy

Contraindicated in the first trimester. Strict indicated in the second and third trimester

Flunitrazepam [1], pregnancy ---> SmPC of [1] of eMC

Strict indication

Fluocinolone acetonide, pregnancy ---> SmPC of [fluocinolone] of eMC

Use in pregnancy is not recommended unless clearly necessary

Fluocinolone, pregnancy

Use in pregnancy is not recommended unless clearly necessary

Fluorescein [1], pregnancy ---> SmPC of [1] of eMC

Due to limited experience, caution should be exercised when considering the use of solution for injection during pregnancy.

Fluorometholone [1], pregnancy ---> SmPC of [1] of eMC

Fluorometholone is not recommended during pregnancy.

Fluorouracil [1], pregnancy ---> SmPC of [1] of eMC

There are no adequate and well-controlled studies in pregnant women, however, fetal defects and miscarriages have been reported.

Fluoxetine [1], pregnancy ---> SmPC of [1] of eMC

Fluoxetine can be used during pregnancy, but caution should be exercised, especially during late pregnancy or just prior to the onset of labour since the following effects have been reported in neonates

Fluoxymesterone, pregnancy

Strict indication

Flupentixol [1], pregnancy ---> SmPC of [1] of eMC

As the safety of this drug during pregnancy has not been established, use during pregnancy, especially the first and last trimesters, should be avoided, unless the expected benefit to the patient outweighs the potential risk to the foetus.

Fluphenazine [1], pregnancy ---> SmPC of [1] of eMC

The safety for the use of this drug during pregnancy has not been established; therefore, the possible hazards should be weighed against the potential benefits when administering this drug to pregnant patients.

Flupirtine, pregnancy

Flupirtine should not be used in pregnant women unless clearly necessary

Fluprednidene, pregnancy

Contraindicated in the first trimester. Strict indication in the second and third trimester

Flurazepam [1], pregnancy ---> SmPC of [1] of eMC

Do not use during pregnancy, especially during the first and last trimesters, unless there are compelling reasons.

Flurbiprofen [1], pregnancy ---> SmPC of [1] of eMC

During the first and second trimester of pregnancy, flurbiprofen should not be given unless clearly necessary. Flurbiprofen is contraindicated during the third trimester of pregnancy.

Fluspirilene, pregnancy

Strict indication

Flutamide, pregnancy

Flutamide is intended for male patients only

Flutemetamol (18 F) [1], pregnancy ---> SmPC of [1] of EMA

Only essential investigations should be carried out during pregnancy, when the likely benefit far exceeds the risk incurred by the mother and foetus.

Fluticasone furoate [1], pregnancy ---> SmPC of [1] of EMA

Fluticasone furoate should be used in pregnancy only if the benefits to the mother outweigh the potential risks to the foetus or child.

Fluticasone furoate/umeclidinium/vilanterol [1], pregnancy ---> SmPC of [1] of EMA

Administration of Trelegy Ellipta to pregnant women should only be considered if the expected benefit to the mother justifies the potential risk to the foetus.

Fluticasone furoate/vilanterol [1], pregnancy ---> SmPC of [1] of EMA

Administration of fluticasone furoate/vilanterol to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.

Fluticasone, pregnancy

Strict indication

Fluvastatin [1], pregnancy ---> SmPC of [1] of eMC

Fluvastatin is contraindicated during pregnancy

Fluvoxamine [1], pregnancy ---> SmPC of [1] of eMC

Fluvoxamine should not be used during pregnancy unless the clinical condition of the woman requires treatment

Folic acid [1], pregnancy ---> SmPC of [1] of eMC

There are no known hazards to the use of folic acid in pregnancy, supplements of folic acid are often beneficial.

Folinic acid [1], pregnancy ---> SmPC of [1] of eMC

There are no indications that folic acid induces harmful effects if administered during pregnancy.

Follitropin alfa [1], pregnancy ---> SmPC of [1] of EMA

There is no indication for use of Ovaleap during pregnancy.

Follitropin alfa/lutropin alfa [1], pregnancy ---> SmPC of [1] of EMA

There is no indication for the use during pregnancy.

Follitropin beta [1], pregnancy ---> SmPC of [1] of EMA

The use of Fertavid during pregnancy is not indicated.

Follitropin delta [1], pregnancy ---> SmPC of [1] of EMA

Studies in animals have shown reproductive toxicity with REKOVELLE doses above the recommended maximal dose in humans

Follitropin, pregnancy

Contraindicated

Fomepizole, pregnancy

Strict indication

Fominoben, pregnancy

It is not recommended during the first trimester of the pregnancy

Fondaparinux [1], pregnancy ---> SmPC of [1] of EMA

Fondaparinux should not be prescribed to pregnant women unless clearly necessary.

Formoterol [1], pregnancy ---> SmPC of [1] of eMC

Until further experience is gained, formoterol is not recommended for use during pregnancy (particularly at the end of pregnancy or during labour) unless there is no more established alternative.

Formoterol/glycopyrronium/budesonide [1], pregnancy ---> SmPC of [1] of EMA

Administration of this medicinal product to pregnant women should only be considered if the expected benefit to the mother justifies the potential risk to the foetus.

Fosamprenavir [1], pregnancy ---> SmPC of [1] of EMA

Telzir should be used during pregnancy only after careful weighing of the potential benefits compared to the potential risk to the foetus

Fosaprepitant [1], pregnancy ---> SmPC of [1] of EMA

IVEMEND should not be used during pregnancy unless clearly necessary.

Foscarnet [1], pregnancy ---> SmPC of [1] of eMC

Foscarnet is not recommended during pregnancy

Fosdenopterin [1], pregnancy ---> SmPC of [1] of EMA

NULIBRY is not recommended during pregnancy and in women of childbearing potential not using contraception.

Fosfomycin [1], pregnancy ---> SmPC of [1] of eMC

Fosfomycin should not be prescribed to pregnant women unless the benefit outweighs the risk.

Fosinopril [1], pregnancy ---> SmPC of [1] of eMC

The use of ACE inhibitors is not recommended during the 1st trimester of pregnancy and are contraindicated during the 2nd and 3rd trimester of pregnancy.

Fosphenytoin [1], pregnancy ---> SmPC of [1] of eMC

If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be informed of the potential harm to the foetus.

Fossil tree, pregnancy

Strict indication

Fostamatinib, pregnancy [2] ---> SmPC of [2] of EMA

Based on findings from animal studies and its mechanism of action, fostamatinib can cause foetal harm when administered to a pregnant woman. Fostamatinib is contraindicated during pregnancy

Fostemsavir [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Rukobia during pregnancy.

Fotemustine, pregnancy

Fotemustine is contraindicated in pregnancy

Framycetin, pregnancy

Contraindicated

Fremanezumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of AJOVY during pregnancy.

Frovatriptan [1], pregnancy ---> SmPC of [1] of eMC

Frovatriptan should not be used during pregnancy unless clearly necessary.

Fulvestrant [1], pregnancy ---> SmPC of [1] of EMA

Faslodex is contraindicated in pregnancy

Furazolidone, pregnancy

Contraindicated

Furosemide [1], pregnancy ---> SmPC of [1] of eMC

The drug should not be used in pregnant women unless the benefits to the patient outweigh the possible risk to the foetus which includes persistence of patent ductus arteriosus

Fusafungine, pregnancy

Caution should be exercised when prescribing to pregnant women.

Fusidic acid [1], pregnancy ---> SmPC of [1] of eMC

No effects during pregnancy are anticipated, since systemic exposure to topically applied fusidic acid/sodium fusidate is negligible. Topical form can be used during pregnancy.

Futibatinib [1], pregnancy ---> SmPC of [1] of EMA

Lytgobi should not be used during pregnancy unless the potential benefit for the women justifies the potential risk to the foetus.

Gabapentin [1], pregnancy ---> SmPC of [1] of eMC

Gabapentin should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the foetus.

Gadobenic acid, pregnancy

Strict indication

Gadobutrol [1], pregnancy ---> SmPC of [1] of eMC

It should not be used during pregnancy unless the clinical condition of the woman requires use of gadobutrol.

Gadodiamide, pregnancy

Should not be used during pregnancy unless clearly necessary

Gadofosveset [1], pregnancy ---> SmPC of [1] of EMA

Should not be used during pregnancy unless clearly necessary

Gadopentetic acid, pregnancy

Should not be used during pregnancy unless clearly necessary

Gadoteric acid, pregnancy

Should not be used during pregnancy unless clearly necessary

Gadoteridol [1], pregnancy ---> SmPC of [1] of eMC

It should not be used during pregnancy unless the clinical condition of the woman requires use of gadoteridol.

Gadoversetamide [1], pregnancy ---> SmPC of [1] of EMA

Optimark should not be used during pregnancy unless the clinical condition of the woman requires use of gadoversetamide.

Gadoxetate [1], pregnancy ---> SmPC of [1] of eMC

It should not be used during pregnancy unless the clinical condition of the woman requires use of gadoxetate.

Galantamine [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing to pregnant women.

Galcanezumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of galcanezumab during pregnancy.

Gallopamil, pregnancy

Contraindicated

Galsulfase [1], pregnancy ---> SmPC of [1] of EMA

Naglazyme should not be used during pregnancy unless clearly necessary.

Ganaxolone [1], pregnancy ---> SmPC of [1] of EMA

ZTALMY is not recommended during pregnancy and in woman of childbearing potential not using contraception.

Ganciclovir, pregnancy

Ganciclovir should not be used during pregnancy unless the potential benefit outweighs the potential teratogenic risk to the foetus.

Ganirelix [1], pregnancy ---> SmPC of [1] of EMA

There are no adequate data from the use of ganirelix in pregnant women. In animals, exposure to ganirelix at the time of implantation resulted in litter resorption. The use of Orgalutran is contraindicated during pregnancy and breast-feeding

Gatifloxacin, pregnancy

Should not be used in pregnant women unless clearly necessary

Gefitinib [1], pregnancy ---> SmPC of [1] of EMA

IRESSA should not be used during pregnancy unless clearly necessary.

Gelatin polysuccinate, pregnancy

Strict indication

Gemcitabine [1], pregnancy ---> SmPC of [1] of eMC

Gemcitabine should not be used during pregnancy unless clearly necessary. Women should be advised not to become pregnant during treatment with gemcitabine and to warn their attending physician immediately, should this occur after all.

Gemfibrozil [1], pregnancy ---> SmPC of [1] of eMC

Gemfibrozil should not be used during pregnancy unless it is clearly necessary.

Gemifloxacin, pregnancy

Should not be used in pregnant women unless clearly necessary

Gemtuzumab ozogamicin [1], pregnancy ---> SmPC of [1] of EMA

MYLOTARG must not be used during pregnancy unless the potential benefit to the mother outweighs the potential risks to the foetus.

Gentamicin [1], pregnancy ---> SmPC of [1] of eMC

In common with most drugs known to cross the placenta, usage in pregnancy should only be considered in life threatening situations where expected benefits outweigh possible risks.

Gestodene, pregnancy

Contraindicated

Gestrinone, pregnancy

Contraindicated

Gilteritinib [1], pregnancy ---> SmPC of [1] of EMA

Xospata is not recommended during pregnancy and in women of childbearing potential not using effective contraception.

Ginger, pregnancy

Strict indication

Ginseng, pregnancy

This drug should not be used during pregnancy and breastfeeding because there is no experience

Givosiran [1], pregnancy ---> SmPC of [1] of EMA

The use of this medicinal product could be considered during pregnancy taking into account the expected health benefit for the woman and potential risks to the foetus.

Glasdegib [1], pregnancy ---> SmPC of [1] of EMA

Glasdegib can cause foetal harm when administered to a pregnant woman. Daurismo should not be used during pregnancy and in women of childbearing potential not using contraception

Glatiramer [1], pregnancy ---> SmPC of [1] of eMC

Glatiramer is contraindicated during pregnancy.

Glecaprevir/pibrentasvir [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, Maviret use is not recommended in pregnancy.

Glibenclamide [1], pregnancy ---> SmPC of [1] of EMA

Glibenclamide should not be administered during pregnancy. It is recommended that oral hypoglycaemic therapy is changed to insulin

Gliclazide [1], pregnancy ---> SmPC of [1] of eMC

Oral hypoglycaemic agents are not suitable, insulin is the drug of first choice for treatment of diabetes during pregnancy.

Glimepiride [1], pregnancy ---> SmPC of [1] of eMC

Glimepiride should not be used during the whole pregnancy.

Glipizide [1], pregnancy ---> SmPC of [1] of eMC

Glipizide is contraindicated in pregnancy.

Gliquidone, pregnancy

Gliquidone should not be administered during pregnancy. It is recommended that oral hypoglycaemic therapy is changed to insulin

Glofitamab [1], pregnancy ---> SmPC of [1] of EMA

Columvi is not recommended during pregnancy and in women of childbearing potential not using contraception. Female patients receiving Columvi should be advised of the potential harm to the foetus.

Glucagon [1], pregnancy ---> SmPC of [1] of EMA

Baqsimi can be used during pregnancy.

Glucagon [1], pregnancy ---> SmPC of [1] of eMC

The use of glucagon has been reported in pregnant women with diabetes and no harmful effects are known with respect to the course of pregnancy and the health of the unborn and the neonate.

Glucarpidase [1], pregnancy ---> SmPC of [1] of EMA

Glucarpidase should only be given to a pregnant woman if clearly needed.

Glucocorticoids, pregnancy

Should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus.

Glucosamine, pregnancy

Glucosamine should not be used during pregnancy

Glucose anhydrous, pregnancy

It should be used with caution during pregnancy. Intravenous glucose may result in considerable foetal insulin production, with an associated risk of rebound hypoglycaemia in the new-born.

Glucose, pregnancy

Strict indication

Glycerin [1], pregnancy ---> SmPC of [1] of eMC

All medicines, should be avoided if possible during pregnancy, and should only be used under a doctor's instruction.

Glycerol phenylbutyrate [1], pregnancy ---> SmPC of [1] of EMA

RAVICTI should not be used during pregnancy and in women of childbearing potential not using contraception unless the clinical condition of the woman requires treatment with glycerol phenylbutyrate

Glycerol trinitrate [1], pregnancy ---> SmPC of [1] of eMC

The administration of glyceryl trinitrate during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.

Glycerol trinitrate, pregnancy

Strict indication

Glycopyrronium [1], pregnancy ---> SmPC of [1] of EMA

Glycopyrronium should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.

Glycopyrronium/formoterol [1], pregnancy ---> SmPC of [1] of EMA

Bevespi Aerosphere should only be used during pregnancy if the expected benefits outweigh the potential risks.

Glycopyrronium/indacaterol/mometasone, pregnancy [2] ---> SmPC of [2] of EMA

This medicinal product should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.

Gold, pregnancy

Strict indication

Golimumab [1], pregnancy ---> SmPC of [1] of EMA

The use of golimumab in pregnant women is not recommended; golimumab should be given to a pregnant woman only if clearly needed.

Gonadorelin [1], pregnancy ---> SmPC of [1] of eMC

Gonadorelin should not be administered to pregnant women

Goserelin [1], pregnancy ---> SmPC of [1] of eMC

Goserelin should not be used during pregnancy since concurrent use of LHRH agonists is associated with a theoretical risk of abortion or foetal abnormality.

Gozetotide [1], pregnancy ---> SmPC of [1] of EMA

All radiopharmaceuticals, including gallium (68Ga) gozetotide, have the potential to cause foetal harm.

Granisetron [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of SANCUSO during pregnancy

Griseofulvin, pregnancy

Griseofulvin is contraindicated during pregnancy

Guaifenesin [1], pregnancy ---> SmPC of [1] of eMC

This product, like most medicines, should not be used during pregnancy unless the potential benefit of treatment to the mother outweighs the possible risks to the developing fetus.

Guanethidine [1], pregnancy ---> SmPC of [1] of eMC

The drug should only be used if there is no safer alternative.

Guanfacin [1], pregnancy ---> SmPC of [1] of EMA

Intuniv is not recommended during pregnancy and in women of childbearing potential not using contraception.

Guselkumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Tremfya in pregnancy.

Haloperidol [1], pregnancy ---> SmPC of [1] of eMC

Haloperidol should be used during pregnancy only if the anticipated benefit outweighs the risk and the administered dose and duration of treatment should be as low and as short as possible.

Helicobacter Test [1], pregnancy ---> SmPC of [1] of EMA

It is not expected that the test procedure may be harmful during pregnancy

Hemine [1], pregnancy ---> SmPC of [1] of eMC

Due to limited data the use of hemin cannot be recommended unless clearly necessary during pregnancy

Hemp extract, pregnancy

Strict indication

Heparin calcium, pregnancy

Heparin calcium should be only administered during the pregnancy as absolute indication

Heparin, pregnancy

Should not be used in pregnant women unless strictly necessary

Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed) [1], pregnancy ---> SmPC of [1] of EMA

This vaccine can be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the foetus.

Hepatitis A vaccine, pregnancy

Vaccination should be postponed until completion of pregnancy

Hepatitis B immunoglobulin [1], pregnancy ---> SmPC of [1] of EMA

Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the fetus and the neonate are to be expected.

Hepatitis B vaccine [1], pregnancy ---> SmPC of [1] of EMA

Vaccination during pregnancy should only be performed if the risk-benefit ratio at individual level outweighs possible risks for the foetus.

Hepatitis B vaccine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of HEPLISAV B during pregnancy. Vaccination during pregnancy should only be performed if the risk-benefit ratio at the individual level outweighs possible risks for the foetus.

Herpes zoster vaccine (live) [1], pregnancy ---> SmPC of [1] of EMA

ZOSTAVAX is not recommended to be administered to pregnant women. In any case, pregnancy should be avoided for one month following vaccination

Hexaminolevulinate, pregnancy

Contraindicated

Hidrosmin, pregnancy

Caution is recommended

Histamine dihydrochloride [1], pregnancy ---> SmPC of [1] of EMA

Ceplene in conjunction with IL-2 must not be used during pregnancy.

Histamine, pregnancy

Contraindicated

Histrelin [1], pregnancy ---> SmPC of [1] of eMC

Due to its indication, it has not been studied in pregnant or breast-feeding women and is not for use in women.

Human alpha1-proteinase inhibitor [1], pregnancy ---> SmPC of [1] of EMA

Respreeza should be given with caution to pregnant women.

Human coagulation factor X [1], pregnancy ---> SmPC of [1] of EMA

Coagadex should be used during pregnancy only if clearly indicated.

Human fibrinogen/human thrombin [1], pregnancy ---> SmPC of [1] of EMA

This medicinal product should be administered to pregnant women only if clinically indicated.

Human hepatitis B immunoglobulin [1], pregnancy ---> SmPC of [1] of EMA

The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women.

Human insulin [1], pregnancy ---> SmPC of [1] of EMA

There are no restrictions on treatment of diabetes with insulin during pregnancy, as insulin does not pass the placental barrier.

Human normal immunoglobulin [1], pregnancy ---> SmPC of [1] of EMA

Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.

Human papillomavirus 9-valent vaccine (recombinant [1], adsorbed), pregnancy ---> SmPC of [1] of EMA

Vaccination should be postponed until completion of pregnancy

Human papillomavirus vaccine [1], pregnancy ---> SmPC of [1] of EMA

Vaccination should be postponed until completion of pregnancy

Human plasma protein [1], pregnancy ---> SmPC of [1] of EMA

Should only be given with caution to pregnant women.

Hyaluronidase [1], pregnancy ---> SmPC of [1] of eMC

Avoid use in pregnancy unless there is no safer alternative.

Hydralazine [1], pregnancy ---> SmPC of [1] of eMC

Hydralazine crosses the placental barrier and is excreted in breast milk. Mothers who are receiving hydralazine should not therefore breast feed their infants.

Hydrochlorothiazide, pregnancy

Hydrochlorothiazid passes the placenta. Its use during the second and third trimester may compromise foeto-placental perfusion

Hydrocodone, pregnancy

Hydrocodone is contraindicated in pregnancy

Hydrocortisone [1], pregnancy ---> SmPC of [1] of EMA

Untreated adrenal insufficiency during pregnancy is associated with poor outcome of both the mother and the foetus, therefore it is important to continue treatment during pregnancy.

Hydrogen peroxide, pregnancy

Strict indication

Hydromorphone [1], pregnancy ---> SmPC of [1] of eMC

Hydromorphone is not recommended in pregnancy as there are insufficient animal or human data to justify such use.

Hydroquinidine, pregnancy

Hydroquinidine is not recommended for use during pregnancy

Hydrotalcite [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing to pregnant women

Hydroxocobalamine [1], pregnancy ---> SmPC of [1] of EMA

There are no adequate data from the use of hydroxocobalamin in pregnant women and the potential risk for humans is unknown.

Hydroxycarbamide [1], pregnancy ---> SmPC of [1] of EMA

Patients on hydroxycarbamide should be made aware of the theoretical risks to the foetus

Hydroxychloroquine [1], pregnancy ---> SmPC of [1] of eMC

Hydroxychloroquine crosses the placenta. It should not be used in pregnancy.

Hydroxyquinoline, pregnancy

Contraindicated

Hydroxyzine [1], pregnancy ---> SmPC of [1] of eMC

Hydroxyzine should not be used during pregnancy

Hymecromone, pregnancy

Strict indication

Ibalizumab [1], pregnancy ---> SmPC of [1] of EMA

Human immunoglobulin (IgG) is known to cross the placental barrier. Ibalizumab is not recommended during pregnancy.

Ibandronic acid [1], pregnancy ---> SmPC of [1] of EMA

Ibandronic acid should not be used during pregnancy.

Ibritumomab tiuxetan [1], pregnancy ---> SmPC of [1] of EMA

Ibritumomab tiuxetan is contraindicated during pregnancy

Ibrutinib [1], pregnancy ---> SmPC of [1] of EMA

IMBRUVICA should not be used during pregnancy.

Ibuprofen [1], pregnancy ---> SmPC of [1] of eMC

Use of ibuprofen should, if possible, be avoided during the first 6 months of pregnancy. During the 3rd trimester, ibuprofen is contraindicated,

Ibutilide, pregnancy

Contraindicated

Icatibant [1], pregnancy ---> SmPC of [1] of EMA

Firazyr should be used during pregnancy only, if the potential benefit justifies the potential risk for the foetus, (e.g for treatment of potentially life threatening laryngeal attacks).

Ichthammol, pregnancy

It should not be used during pregnancy

Icosapent ethyl [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of icosapent ethyl during pregnancy unless the benefit of use outweighs the potential risk to the foetus.

Idarubicin [1], pregnancy ---> SmPC of [1] of eMC

Idarubicin should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Idarucizumab [1], pregnancy ---> SmPC of [1] of EMA

Praxbind may be used during pregnancy, if the expected clinical benefit outweighs the potential risks.

Idebenone [1], pregnancy ---> SmPC of [1] of EMA

Idebenone should only be administered to pregnant women or women of child-bearing age likely to become pregnant if it is considered that the benefit of the therapeutic effect outweighs any potential risk.

Idecabtagene vicleucel [1], pregnancy ---> SmPC of [1] of EMA

Abecma is not recommended for women who are pregnant or for women of childbearing potential not using contraception. Pregnant women should be advised on the potential risks to the foetus.

Idelalisib [1], pregnancy ---> SmPC of [1] of EMA

Zydelig is not recommended during pregnancy and in women of childbearing potential not using contraception.

Idoxuridine, pregnancy

Should not be used in pregnant women unless strictly necessary

Idursulfase [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of idursulfase during pregnancy.

Ifosfamide, pregnancy

Ifosfamide is contraindicated in pregnancy

Iloprost [1], pregnancy ---> SmPC of [1] of EMA

Taking into account the potential maternal benefit, the use of Ventavis during pregnancy may be considered in those women who choose to continue their pregnancy, despite the known risks of pulmonary hypertension during pregnancy.

Imatinib [1], pregnancy ---> SmPC of [1] of EMA

Glivec should not be used during pregnancy unless clearly necessary. If it is used during pregnancy, the patient must be informed of the potential risk to the foetus.

Imidapril [1], pregnancy ---> SmPC of [1] of eMC

The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors is contraindicated during the second and third trimester of pregnancy

Imiglucerase [1], pregnancy ---> SmPC of [1] of EMA

The use of Cerezyme could be beneficial to control the underlying Gaucher disease in pregnancy. Foetal demise has been reported rarely

Imipenem/cilastatin [1], pregnancy ---> SmPC of [1] of eMC

Imipenem/Cilastatin 500 mg/500 mg Powder for Solution for Infusion should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Imipenem/cilastatin/relebactam [1], pregnancy ---> SmPC of [1] of EMA

Recarbrio should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Imipramine [1], pregnancy ---> SmPC of [1] of eMC

Treatment with imipramine should be avoided during pregnancy, unless the anticipated benefits justify the potential risk to the foetus.

Imiquimod [1], pregnancy ---> SmPC of [1] of EMA

Zyclara should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Imlifidase [1], pregnancy ---> SmPC of [1] of EMA

There are no data from use of imlifidase in pregnant women since pregnancy is a contraindication to kidney transplantation. As a precautionary measure, it is preferable to avoid the use of imlifidase during pregnancy.

Immunocyanin, pregnancy

Should not be used in pregnant women unless strictly necessary

Inclisiran [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of inclisiran during pregnancy.

Indacaterol [1], pregnancy ---> SmPC of [1] of EMA

Oslif Breezhaler should only be used during pregnancy if the expected benefits outweigh the potential risks

Indacaterol/glycopyrronium [1], pregnancy ---> SmPC of [1] of EMA

Xoterna Breezhaler should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.

Indacaterol/mometasone [1], pregnancy ---> SmPC of [1] of EMA

This medicinal product should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.

Indapamide [1], pregnancy ---> SmPC of [1] of eMC

As a general rule, the administration of diuretics should be avoided in pregnant women and should never be used to treat physiological oedema of pregnancy. Diuretics can cause foetoplacental ischaemia, with a risk of impaired foetal growth

Indinavir [1], pregnancy ---> SmPC of [1] of EMA

Indinavir should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus

Indobufen, pregnancy

Not recommended during the pregnancy

Indocyanine green, pregnancy

Strict indication

Indometacin [1], pregnancy ---> SmPC of [1] of eMC

Indometacin should be used during the first two trimesters of pregnancy only if the potential benefit justifies the potential risk to the foetus. Use of indometacin during the third trimester of pregnancy is not recommended.

Infliximab [1], pregnancy ---> SmPC of [1] of EMA

The available clinical experience is too limited to exclude a risk, and administration of infliximab is therefore not recommended during pregnancy.

Influenza vaccine (H1N1)v (split virion [1], inactivated, adjuvanted), pregnancy ---> SmPC of [1] of EMA

Data from pregnant women vaccinated with different inactivated non-adjuvanted seasonal vaccines do not suggest malformations or fetal or neonatal toxicity.

Influenza vaccine (live attenuated; nasal) [1], pregnancy ---> SmPC of [1] of EMA

Fluenz Tetra is not recommended during pregnancy.

Influenza vaccine (split virion [1], inactivated), pregnancy ---> SmPC of [1] of EMA

This vaccine is intended for individuals 60 years of age and over. Therefore, this information is not applicable.

Influenza vaccine (surface antigen [1], inactivated, prepared in cell cultures), pregnancy ---> SmPC of [1] of EMA

The use of Optaflu may be considered from the second trimester of pregnancy.

Influenza vaccine, pregnancy

The use may be considered during pregnancy if this is thought to be necessary

Ingenol mebutate [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Picato during pregnancy.

Inosine, pregnancy

Contraindicated

Inositol nicotinate, pregnancy

Should not be used in pregnant women unless clearly necessary

Inotersen [1], pregnancy ---> SmPC of [1] of EMA

Due to the potential teratogenic risk arising from unbalanced vitamin A levels, inotersen should not be used during pregnancy, unless the clinical condition of the woman requires treatment with inotersen.

Inotuzumab ozogamicin [1], pregnancy ---> SmPC of [1] of EMA

BESPONSA must not be used during pregnancy unless the potential benefit to the mother outweighs the potential risks to the foetus.

Insulin aspart [1], pregnancy ---> SmPC of [1] of EMA

NovoRapid (insulin aspart) can be used in pregnancy.

Insulin degludec [1], pregnancy ---> SmPC of [1] of EMA

In general, intensified blood glucose control and monitoring of pregnant women with diabetes are recommended throughout pregnancy and when contemplating pregnancy.

Insulin degludec/insulin aspart [1], pregnancy ---> SmPC of [1] of EMA

In general, intensified blood glucose control and monitoring of pregnant women with diabetes are recommended throughout pregnancy and when contemplating pregnancy.

Insulin degludec/liraglutide [1], pregnancy ---> SmPC of [1] of EMA

If a patient wishes to become pregnant, or pregnancy occurs, treatment with insulin Xultophy should be discontinued.

Insulin detemir [1], pregnancy ---> SmPC of [1] of EMA

Treatment can be considered during pregnancy, but any potential benefit must be weighed against a possibly increased risk of an adverse pregnancy outcome.

Insulin glargin [1], pregnancy ---> SmPC of [1] of EMA

The use of Toujeo may be considered during pregnancy, if clinically needed.

Insulin glargine/lixisenatide [1], pregnancy ---> SmPC of [1] of EMA

Suliqua should not be used during pregnancy. If a patient wishes to become pregnant, or pregnancy occurs, treatment with Suliqua should be discontinued.

Insulin glulisin [1], pregnancy ---> SmPC of [1] of EMA

Caution should be exercised when prescribing to pregnant women. Careful monitoring of glucose control is essential.

Insulin lispro [1], pregnancy ---> SmPC of [1] of EMA

Data on a large number of exposed pregnancies do not indicate any adverse effect of insulin lispro on pregnancy or on the health of the foetus/newborn.

Insulin, pregnancy

Both hypoglycaemia and hyperglycaemia, which can occur in inadequately controlled diabetes therapy, increase the risk of malformations and death in utero

Interferon alfa, pregnancy

Is to be used during pregnancy only if the potential benefit justifies the potential risk to the foetus

Interferon alfa-2a, pregnancy

Strict indication

Interferon alfa-2b [1], pregnancy ---> SmPC of [1] of EMA

IntronA is to be used during pregnancy only if the potential benefit justifies the potential risk to the foetus

Interferon alfa-2b/ribavirin, pregnancy

The therapy of interferon alfa-2b with ribavirin is contraindicated in women who are pregnant.

Interferon beta-1a [1], pregnancy ---> SmPC of [1] of EMA

Initiation of treatment is contraindicated during pregnancy

Interferon beta-1b [1], pregnancy ---> SmPC of [1] of EMA

Initiation of treatment is contraindicated during pregnancy. If a patient becomes pregnant or plans to become pregnant while using Extavia, she should be informed of the potential hazards and discontinuation of therapy should be considered

Interferon gamma-1b, pregnancy

Should be used during pregnancy only if clearly needed

Interferon, pregnancy

Spontaneous abortions have been reported in subjects with MS in controlled clinical trials. Women of childbearing potential should take appropriate contraceptive measures.

Interleukin-2 [1], pregnancy ---> SmPC of [1] of eMC

Interleukin-2 should not be used during pregnancy unless the potential benefit to the patient justifies the potential risk to the foetus.

Inulin, pregnancy

Strict indication

Iobitridol, pregnancy

Contraindicated

Iodinated contrast media, pregnancy

Contraindicated

Iodine, pregnancy

Should not be used during pregnancy

Iodixanol, pregnancy

An exposure to radiation should be avoided during pregnancy

Iodoform, pregnancy

Should not be used during pregnancy

Ioflupane [1], pregnancy ---> SmPC of [1] of EMA

DaTSCAN is contraindicated in pregnancy

Iohexol, pregnancy

Iohexol should not be used in pregnancy unless the benefit outweighs the risk and it is considered essential by the physician.

Iomeprol [1], pregnancy ---> SmPC of [1] of eMC

Since, wherever possible, exposure to radiation should be avoided during pregnancy, the benefits of any X-ray examination, whether with or without contrast material, should be carefully weighed against the possible risk.

Iopamidol [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure, it is preferable to avoid the use of Iopamidol solution during pregnancy.

Iopromide, pregnancy

Adequate and well-controlled studies in pregnant women have not been conducted.

Iosarcol, pregnancy

Contraindicated

Iotrolan, pregnancy

Strict indication

Ioxaglic acid, pregnancy

Contraindicated

Ioxitalamic acid, pregnancy

Strict indication

Ipecac, pregnancy

Contraindicated

Ipilimumab [1], pregnancy ---> SmPC of [1] of EMA

YERVOY is not recommended during pregnancy or in women of childbearing potential not using effective contraception, unless the clinical benefit outweighs the potential risk.

Ipratropium [1], pregnancy ---> SmPC of [1] of eMC

The benefits of using ipratropium bromide during a confirmed or suspected pregnancy must be weighed against the possible hazards to the unborn child.

Irbesartan [1], pregnancy ---> SmPC of [1] of EMA

The use of AIIRAs is not recommended during the first trimester of pregnancy. The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy

Irbesartan/hydrochlorothiazide [1], pregnancy ---> SmPC of [1] of EMA

Is not recommended during the first trimester of pregnancy. Is contraindicated during the second and third trimesters of pregnancy.

Irinotecan [1], pregnancy ---> SmPC of [1] of EMA

Based on results from animal studies and the mechanism of action of irinotecan, ONIVYDE should not be used during pregnancy unless clearly necessary.

Isatuximab [1], pregnancy ---> SmPC of [1] of EMA

The use of isatuximab in pregnant women is not recommended.

Isavuconazole [1], pregnancy ---> SmPC of [1] of EMA

CRESEMBA must not be used during pregnancy except in patients with severe or potentially life-threatening fungal infections, in whom isavuconazole may be used if the anticipated benefits outweigh the possible risks to the foetus.

Isocarboxazid [1], pregnancy ---> SmPC of [1] of eMC

Do not use in pregnancy, especially during the first and last trimesters, unless there are compelling reasons.

Isoflurane [1], pregnancy ---> SmPC of [1] of eMC

Isoflurane should only be used during pregnancy if the benefit outweighs the potential risk.

Isoniazid [1], pregnancy ---> SmPC of [1] of eMC

There is a possibility of an increased risk of foetal malformations occurring when isoniazid is given in early pregnancy. If pregnancy cannot be excluded possible risks should be balanced against therapeutic benefits.

Isoprenaline, pregnancy

Due to the inhibitor effect of uterine contraction of isoprenaline, it should be used with caution close to delivery

Isosorbide dinitrate [1], pregnancy ---> SmPC of [1] of eMC

This product should not be used during pregnancy unless considered essential by the physician.

Isosorbide mononitrate [1], pregnancy ---> SmPC of [1] of eMC

It is not advisable to use this drug during pregnancy.

Isothipendyl, pregnancy

Should not be used during pregnancy

Isotretinoin [1], pregnancy ---> SmPC of [1] of eMC

Pregnancy is an absolute contraindication to treatment with isotretinoin

Isradipine [1], pregnancy ---> SmPC of [1] of eMC

There is insufficient experience with the drug in pregnant women to justify its use during pregnancy unless the benefit to the mother is expected to outweigh any potential risk to the infant.

Itraconazol [1], pregnancy ---> SmPC of [1] of eMC

Itraconazole must not be used during pregnancy except for life-threatening cases where the potential benefit to the mother outweighs the potential harm to the fetus

Ivabradine [1], pregnancy ---> SmPC of [1] of EMA

Ivabradine is contra-indicated during pregnancy

Ivacaftor [1], pregnancy ---> SmPC of [1] of EMA

Kalydeco should be used during pregnancy only if clearly needed.

Ivacaftor/tezacaftor/elexacaftor [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of IVA/TEZ/ELX during pregnancy.

Ivermectine, pregnancy

Contraindicated

Ivosidenib [1], pregnancy ---> SmPC of [1] of EMA

Tibsovo is not recommended for use during pregnancy and in women of childbearing potential not using effective contraception. Patients should be informed of the potential risk to the foetus

Ixabepilone, pregnancy

It may cause fetal harm

Ixazomib [1], pregnancy ---> SmPC of [1] of EMA

NINLARO is not recommended during pregnancy as it can cause foetal harm when administered to a pregnant woman. Therefore, women should avoid becoming pregnant while being treated with NINLARO.

Ixekizumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Taltz during pregnancy.

Japanese encephalitis vaccine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, the use of IXIARO during pregnancy should be avoided.

Josamycin, pregnancy

Strict indication in the first trimester of pregnancy

Kanamycin, pregnancy

The aminoglycoside antibiotic crosses the placenta. Contraindicated

Kebuzone, pregnancy

Contraindicated

Ketamine [1], pregnancy ---> SmPC of [1] of eMC

Ketamine crosses the placenta. The safe use in pregnancy has not been established and such use is not recommended.

Ketoconazole [1], pregnancy ---> SmPC of [1] of EMA

Ketoconazole HRA is contraindicated during pregnancy and it should not be used in women of childbearing potential not using an effective method of contraception

Ketoprofen [1], pregnancy ---> SmPC of [1] of eMC

During the first and second trimester of pregnancy, ketoprofen should not be given unless clearly necessary. Ketoprofen is contraindicated during the third trimester of pregnancy.

Ketorolac [1], pregnancy ---> SmPC of [1] of eMC

Ketorolac crosses the placenta to the extent of approximately 10%. Ketorolac is contraindicated in pregnancy, labour or delivery

Ketotifen [1], pregnancy ---> SmPC of [1] of eMC

Although there is no evidence of any teratogenic effect, recommendation for ketotifen in pregnancy cannot be given.

Labetalol, pregnancy

Labetalol crosses the placenta. Labetalol should be only used in the first trimester of pregnancy if unless the potential benefit outweighs the potential risk

Lacidipine [1], pregnancy ---> SmPC of [1] of eMC

Lacidipine should only be used in pregnancy when the potential benefits for the mother outweigh the possibility of adverse effects in the foetus or neonate.

Lacosamide [1], pregnancy ---> SmPC of [1] of EMA

Lacosamide should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus).

Lactitol, pregnancy

Lactitol should not be used during the first trimester of pregnancy unless strictly necessary

Lactulose [1], pregnancy ---> SmPC of [1] of eMC

Lactulose can be used during pregnancy.

Lamivudine [1], pregnancy ---> SmPC of [1] of EMA

Zeffix can be used during pregnancy if clinically needed.

Lamivudine/raltegravir [1], pregnancy ---> SmPC of [1] of EMA

DUTREBIS  should not be used during pregnancy.

Lamivudine/zidovudine [1], pregnancy ---> SmPC of [1] of EMA

The malformative risk is unlikely in humans based on the large amount of data.

Lamotrigine [1], pregnancy ---> SmPC of [1] of eMC

If therapy with lamotrigine is considered necessary during pregnancy, the lowest possible therapeutic dose is recommended.

Lanadelumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of lanadelumab during pregnancy.

Lanreotide [1], pregnancy ---> SmPC of [1] of eMC

Lanreotide should be administered to pregnant women only if clearly needed.

Lansoprazole [1], pregnancy ---> SmPC of [1] of eMC

The use of lansoprazole during pregnancy is not recommended.

Lanthanum carbonate [1], pregnancy ---> SmPC of [1] of eMC

Lanthanum carbonate is not recommended for use during pregnancy.

Lapatinib [1], pregnancy ---> SmPC of [1] of EMA

Should not be used during pregnancy unless clearly necessary

Laronidase [1], pregnancy ---> SmPC of [1] of EMA

Aldurazyme should not be used during pregnancy unless clearly needed

Laropiprant/nicotinic acid [1], pregnancy ---> SmPC of [1] of EMA

Pelzont should not be used during pregnancy unless clearly necessary.

Larotrectinib [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of VITRAKVI during pregnancy.

Lasofoxifene, pregnancy

Lasofoxifene is only for use in postmenopausal women

Latanoprost [1], pregnancy ---> SmPC of [1] of eMC

It has potential hazardous pharmacological effects with respect to the course of pregnancy, to the unborn or the neonate. Therefore, it should not be used during pregnancy.

Latanoprost/netarsudil [1], pregnancy ---> SmPC of [1] of EMA

Latanoprost has potentially harmful pharmacological effects during pregnancy and/or on the fetus/newborn child (see section 5.3). Therefore, latanoprost + netarsudil should not be used during pregnancy.

Latanoprost/timolol [1], pregnancy ---> SmPC of [1] of eMC

Latanoprost/Timolol should not be used during pregnancy

Ledipasvir/sofosbuvir [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Harvoni during pregnancy.

Lefamulin [1], pregnancy ---> SmPC of [1] of EMA

Xenleta is not recommended during pregnancy.

Leflunomide [1], pregnancy ---> SmPC of [1] of EMA

Leflunomide Winthrop is contraindicated in pregnancy

Lenacapavir [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Sunlenca during pregnancy unless the clinical condition of the women requires treatment with Sunlenca.

Lenalidomide [1], pregnancy ---> SmPC of [1] of EMA

A teratogenic effect of lenalidomide is expected and lenalidomide is contraindicated during pregnancy

Lenograstim [1], pregnancy ---> SmPC of [1] of eMC

Lenograstim should not be used during pregnancy unless clearly necessary.

Lenvatinib [1], pregnancy ---> SmPC of [1] of EMA

Lenvatinib should not be used during pregnancy unless clearly necessary and after a careful consideration of the needs of the mother and the risk to the foetus.

Lepirudin [1], pregnancy ---> SmPC of [1] of EMA

Should not be used during pregnancy

Lercanidipine [1], pregnancy ---> SmPC of [1] of eMC

Lercanidipine should not be administered during pregnancy or to women with child-bearing potential unless effective contraception is used.

Lesinurad [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Zurampic during pregnancy. Female patients of childbearing potential should not rely on hormonal contraception alone when taking Zurampic

Letermovir [1], pregnancy ---> SmPC of [1] of EMA

PREVYMIS is not recommended during pregnancy and in women of childbearing potential not using contraception.

Letrozol [1], pregnancy ---> SmPC of [1] of eMC

Letrozole is contraindicated during pregnancy

Leuprorelin [1], pregnancy ---> SmPC of [1] of EMA

CAMCEVI is contraindicated in women. Based on findings in animals and mechanism of action, leuprorelin may impair fertility in males of reproductive potential

Levacetylmethadol [1], pregnancy ---> SmPC of [1] of EMA

The use of this product is contra-indicated during pregnancy.

Levetiracetam [1], pregnancy ---> SmPC of [1] of EMA

Keppra is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary.

Levobunolol [1], pregnancy ---> SmPC of [1] of eMC

Levobunolol should not be used during pregnancy unless clearly necessary

Levobupivacaine [1], pregnancy ---> SmPC of [1] of eMC

Levobupivacaine should not be given during early pregnancy unless clearly necessary.

Levocabastine, pregnancy

Levocabastine should not be used during pregnancy, unless the potential benefit justifies the potential risk to the foetus.

Levocetirizine [1], pregnancy ---> SmPC of [1] of eMC

Caution should be exercised when prescribing to lactating women.

Levodopa, pregnancy [2] ---> SmPC of [2] of EMA

Inbrija is not recommended during pregnancy and in women of childbearing potential not using contraception.

Levodopa/benserazide [1], pregnancy ---> SmPC of [1] of eMC

It is contra-indicated in pregnancy

Levodopa/carbidopa [1], pregnancy ---> SmPC of [1] of EMA

Numient is not recommended during pregnancy and in women of childbearing potential not using contraception, unless the benefits for the mother outweigh the possible risks to the foetus.

Levodopa/carbidopa/entacapone [1], pregnancy ---> SmPC of [1] of EMA

Corbilta should not be used during pregnancy unless the benefits for the mother outweigh the possible risks to the foetus.

Levodropropizine, pregnancy

Levodropropizine is contraindicated in pregnancy

Levofloxacin [1], pregnancy ---> SmPC of [1] of EMA

In the absence of human data and findings in non-clinical studies suggesting a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, use of Quinsair is contraindicated during pregnancy

Levofolinic acid [1], pregnancy ---> SmPC of [1] of eMC

No formal animal reproductive toxicity studies with disodium levofolinate have been conducted.

Levomepromazine, pregnancy

The use of levomepromazine is not recommend during pregnancy

Levomethadone, pregnancy

Levomethadone passes the placenta.

Levonorgestrel [1], pregnancy ---> SmPC of [1] of eMC

Levonorgestrel should not be given to pregnant women

Levonorgestrel/ethinylestradiol [1], pregnancy ---> SmPC of [1] of eMC

This medicinal product is not indicated during pregnancy.

Levosimendan, pregnancy

It should only be used during pregnancy if the expected benefits outweigh the potential risks

Levosulpiride, pregnancy

Levosulpiride is contraindicated in pregnancy

Levothyroxine [1], pregnancy ---> SmPC of [1] of eMC

Any possible risk of foetal abnormalities should be weighed against the risk to the foetus of untreated hypothyroidism.

Lidocaine [1], pregnancy ---> SmPC of [1] of eMC

Lidocaine should not be administered during early pregnancy unless the benefits are considered to outweigh the risks.

Lidocaine/prilocaine [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Fortacin during pregnancy unless effective male barrier contraceptive measures are taken in order to avoid potential foetal exposure.

Light paraffin [1], pregnancy ---> SmPC of [1] of eMC

No effects during pregnancy are anticipated, since systemic exposure to Oilatum Emollient is expected to be low.

Linaclotide [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use during pregnancy.

Linagliptin [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of linagliptin during pregnancy.

Linagliptin/metformin [1], pregnancy ---> SmPC of [1] of EMA

Jentadueto should not be used during pregnancy.

Lincomycin, pregnancy

Lincomycin passes the placenta

Linezolid [1], pregnancy ---> SmPC of [1] of eMC

Linezolid should not be used during pregnancy unless clearly necessary i.e. only if the potential benefit outweighs the theoretical risk.

Liothyronine [1], pregnancy ---> SmPC of [1] of eMC

Any possible risk of foetal abnormalities should be weighed against the risk to the foetus of untreated hypothyroidism.

Lipegfilgrastim [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Lonquex during pregnancy.

Liposomal bupivacaine [1], pregnancy ---> SmPC of [1] of EMA

EXPAREL liposomal is not recommended during pregnancy and in women of childbearing potential not using contraception.

Liposome-encapsulated doxorubicin-citrate complex [1], pregnancy ---> SmPC of [1] of EMA

Due to the known cytotoxic, mutagenic and embryotoxic properties of doxorubicin, Myocet should not be used during pregnancy unless clearly necessary.

Liraglutide [1], pregnancy ---> SmPC of [1] of EMA

Liraglutide should not be used during pregnancy, and the use of insulin is recommended instead

Lisdexamfetamine [1], pregnancy ---> SmPC of [1] of eMC

Dexamfetamine, the active metabolite of lisdexamfetamine, crosses the placenta. Lisdexamfetamine should only be used during pregnancy if the potential benefit justifies the potential risk to the foetus.

Lisinopril [1], pregnancy ---> SmPC of [1] of eMC

The use of ACE inhibitors is not recommended during the first trimester of pregnancy. The use of ACE inhibitors is contraindicated during the second and third trimester of pregnancy

Lisinopril/hydrochlorothiazide [1], pregnancy ---> SmPC of [1] of eMC

The use of ACE inhibitors is not recommended during the 1st trimester of pregnancy and are contraindicated during the 2nd and 3rd trimester of pregnancy.

Lisocabtagene maraleucel [1], pregnancy ---> SmPC of [1] of EMA

Breyanzi is not recommended for women who are pregnant, or for women of childbearing potential not using contraception. Pregnant women should be advised on the potential risks to the foetus.

Lisuride, pregnancy

It is not recommended using lisuride in pregnancy

Lithium carbonate [1], pregnancy ---> SmPC of [1] of eMC

Lithium therapy should not be used during pregnancy, especially during the first trimester, unless considered essential.

Lithium, pregnancy ---> SmPC of [lithium carbonate] of eMC

Lithium therapy should not be used during pregnancy, especially during the first trimester, unless considered essential.

Live varicella vaccine, pregnancy

The vaccine is not indicated in individuals less than 60 years of age. In any case, pregnancy should be avoided for 3 months following vaccination

Lixisenatide [1], pregnancy ---> SmPC of [1] of EMA

Lyxumia should not be used during pregnancy. The use of insulin is recommended instead. If a patient wishes to become pregnant, or pregnancy occurs, treatment with Lyxumia should be discontinued.

Lodoxamide [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure, it is preferable to avoid the use of lodoxamide during pregnancy.

Lofepramine [1], pregnancy ---> SmPC of [1] of eMC

The administration of lofepramine in pregnancy is not advised unless there are compelling medical reasons.

Lomefloxacin, pregnancy

Tablets: Contraindicated. Eye drops: Strict indication

Lomitapide [1], pregnancy ---> SmPC of [1] of EMA

Lojuxta is contraindicated during pregnancy.

Lomustine [1], pregnancy ---> SmPC of [1] of eMC

Lomustine is contraindicated in women who are pregnant

Lonafarnib [1], pregnancy ---> SmPC of [1] of EMA

Lonafarnib is not recommended during pregnancy and in women of childbearing potential not using contraception.

Lonapegsomatropin [1], pregnancy ---> SmPC of [1] of EMA

Lonapegsomatropin Ascendis Pharma is not recommended during pregnancy and in women of childbearing potential not using contraception.

Loncastuximab tesirine [1], pregnancy ---> SmPC of [1] of EMA

Zynlonta is not recommended during pregnancy unless the potential benefit for the woman outweighs the potential risk to the foetus.

Lonoctocog alfa [1], pregnancy ---> SmPC of [1] of EMA

Factor VIII should be used during pregnancy and lactation only if clearly indicated.

Loperamide [1], pregnancy ---> SmPC of [1] of eMC

As with other drugs, it is not advisable to administer loperamide in pregnancy, especially during the first trimester.

Lopinavir, pregnancy

Only if clearly indicated

Lopinavir/ritonavir [1], pregnancy ---> SmPC of [1] of EMA

Based on the limited data, the malformative risk is unlikely in humans. Lopinavir can be used during pregnancy if clinically needed.

Loprazolam, pregnancy

During pregnancy, a benzodiazepine may be administered only if there is a compelling indication.

Loratadine [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure, it is preferable to avoid the use of loratadine during pregnancy.

Lorazepam [1], pregnancy ---> SmPC of [1] of eMC

Benzodiazepines should not be used during pregnancy, especially during the first and last trimesters. Benzodiazepines may cause foetal damage when administered to pregnant women.

Lorlatinib [1], pregnancy ---> SmPC of [1] of EMA

Lorlatinib may cause foetal harm when administered to a pregnant woman. Lorlatinib is not recommended during pregnancy or for women of childbearing potential not using contraception.

Lormetazepam, pregnancy

Benzodiazepines should not be used during pregnancy, especially during the first and last trimesters. Benzodiazepines may cause foetal damage when administered to pregnant women.

Lornoxicam, pregnancy

Lornoxicam is contraindicated in the third trimester of pregnancy and should not be used during the first and second trimester and during the labour

Losartan [1], pregnancy ---> SmPC of [1] of eMC

The use of AIIRAs is not recommended during the first trimester of pregnancy. The use of AIIRAs is contra-indicated during the 2nd and 3rd trimesters of pregnancy

Losartan/hydrochlorothiazide [1], pregnancy ---> SmPC of [1] of eMC

The use of AIIRAs is not recommended during the first trimester of pregnancy. The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy

Loteprednol [1], pregnancy ---> SmPC of [1] of eMC

Loteprednol should not be used in pregnancy unless clearly necessary.

Lovastatine, pregnancy

Lovastatine is contraindicated during pregnancy

Loxapine [1], pregnancy ---> SmPC of [1] of EMA

ADASUVE should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Lumacaftor/ivacaftor [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of lumacaftor/ivacaftor during pregnancy unless the clinical condition of the mother requires treatment with lumacaftor/ivacaftor.

Lumasiran [1], pregnancy ---> SmPC of [1] of EMA

The use of this medicinal product could be considered during pregnancy taking into account the expected health benefit for the woman and potential risks to the foetus.

Lumefantrine, pregnancy

Strict indication

Lumiracoxib, pregnancy

Strict indication in the first and second trimester. Contraindicated in the third trimester

Lurasidone [1], pregnancy ---> SmPC of [1] of EMA

Lurasidone should not be used during pregnancy unless clearly necessary.

Luspatercept [1], pregnancy ---> SmPC of [1] of EMA

Reblozyl is contraindicated during pregnancy. Women of childbearing potential have to use effective contraception during treatment with Reblozyl and for at least 3 months after the last dose.

Lusutrombopag [1], pregnancy ---> SmPC of [1] of EMA

Lusutrombopag is not recommended during pregnancy and in women of child-bearing potential not using contraception.

Lutetium (177Lu) chloride [1], pregnancy ---> SmPC of [1] of EMA

The use of Lutetium (177Lu)-labelled medicinal products is contraindicated during established or suspected pregnancy or when pregnancy has not been excluded

Lutetium (177Lu) oxodotreotide [1], pregnancy ---> SmPC of [1] of EMA

The use of Lutathera is contraindicated during established or suspected pregnancy or when pregnancy has not been excluded due to the risk associated with the ionizing radiation

Lutropin alfa [1], pregnancy ---> SmPC of [1] of EMA

There is no indication for the use of lutropin alfa during pregnancy.

Macimorelin [1], pregnancy ---> SmPC of [1] of EMA

Macimorelin is not recommended during pregnancy.

Macitentan [1], pregnancy ---> SmPC of [1] of EMA

Opsumit is contraindicated during pregnancy and in women of childbearing potential who are not using reliable contraception

Macrosalb, pregnancy

Radionuclide procedures carried out on pregnant women also involve radiation doses to the fetus. Only imperative investigations should be carried out during pregnancy, when likely benefit exceeds the risks incurred by mother and fetus.

Magaldrate, pregnancy

Only short-term and the lowest possible dose to avoid an aluminium burden for the fetus

Magnesium hydroxide [1], pregnancy ---> SmPC of [1] of eMC

As with all other medicines, use of this product should be avoided unless recommended by a doctor.

Mangafodipir [1], pregnancy ---> SmPC of [1] of EMA

Mangafodipir must not be used during pregnancy

Manidipine, pregnancy

For security reasons, manidipine should not be used during pregnancy

Mannitol [1], pregnancy ---> SmPC of [1] of EMA

Caution should be exercised when prescribing Bronchitol to pregnant women. As a precautionary measure, it is preferable to avoid the use of Bronchitol during pregnancy

Maprotiline, pregnancy

Maprotiline may only be used during pregnancy after a careful benefit/risk assessment

Maralixibat [1], pregnancy ---> SmPC of [1] of EMA

No effects on the foetus during pregnancy are anticipated, since systemic exposure to maralixibat is negligible. As a precautionary measure, it is preferable to avoid the use of Livmarli during pregnancy.

Maraviroc [1], pregnancy ---> SmPC of [1] of EMA

Maraviroc should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Mazindol, pregnancy

Contraindicated

Measles vaccine, pregnancy

Contraindicated

Measles [1], mumps, and rubella vaccine (live), pregnancy ---> SmPC of [1] of EMA

Pregnant women should not be vaccinated with M-M-RVAXPRO. Pregnancy should be avoided for 1 month following vaccination. Women who intend to become pregnant should be advised to delay.

Measles [1], mumps, rubella and varicella vaccine (live), pregnancy ---> SmPC of [1] of EMA

Pregnant women should not be vaccinated with ProQuad.

Measles, mumps, and rubella vaccine (live), pregnancy

The vaccine should not be administered to pregnancy; furthermore, pregnancy should be avoided for 3 months following vaccination

Mebendazol [1], pregnancy ---> SmPC of [1] of eMC

Since mebendazole is contra-indicated in pregnancy, patients who think they are, or may be, pregnant should not take this preparation.

Mebeverine [1], pregnancy ---> SmPC of [1] of eMC

Mebeverine is not recommended during pregnancy.

Mecasermin [1], pregnancy ---> SmPC of [1] of EMA

INCRELEX should not be used during pregnancy unless clearly necessary.

Meclocycline, pregnancy

Strict indication

Medazepam, pregnancy

During pregnancy, a benzodiazepine may be administered only if there is a compelling indication.

Medicated sponge [1], pregnancy ---> SmPC of [1] of EMA

Should be administered to pregnant women only if clearly needed.

Medronic acid, pregnancy

Strict indication

Medroxyprogesterone [1], pregnancy ---> SmPC of [1] of eMC

Medroxyprogesterone acetate is contraindicated in women who are pregnant.

Mefloquine [1], pregnancy ---> SmPC of [1] of eMC

Mefloquine should not be used during pregnancy particularly in the first trimester unless the expected benefit justifies the potential risk to the foetus.

Megergoline, pregnancy

Contraindicated

Megestrol [1], pregnancy ---> SmPC of [1] of eMC

Megestrol is not recommended for women who are pregnant

Meglumine and sodium ioxitalamate, pregnancy

Should not be used during pregnancy unless clearly necessary

Meglumine ioxitalamate, pregnancy

Should not be used during pregnancy unless clearly necessary. The intrauterin administration is contraindicated

Melagatran, pregnancy

Should not be used during pregnancy unless clearly needed

Melatonin [1], pregnancy ---> SmPC of [1] of EMA

In view of the lack of clinical data, use in pregnant women and by women intending to become pregnant is not recommended.

Melitracen, pregnancy

Strict indication, especially in the first and third trimester

Meloxicam, pregnancy

Strict indication in first and second trimester. Contraindicated in third trimester

Melperone, pregnancy

Melperone should not be prescribed during pregnancy

Melphalan [1], pregnancy ---> SmPC of [1] of EMA

HSCT is contraindicated in pregnant women. Therefore melphalan is contraindicated during pregnancy for this indication

Memantin [1], pregnancy ---> SmPC of [1] of EMA

Memantine should not be used during pregnancy unless clearly necessary.

Meningococcal group A; C; W-135 and Y conjugate vaccine [1], pregnancy ---> SmPC of [1] of EMA

Nimenrix should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the foetus.

Meningococcal group B vaccine [1], pregnancy ---> SmPC of [1] of EMA

Vaccination should not be withheld when there is a clear risk of exposure to meningococcal infection

Meningococcal polysaccharide vaccine, pregnancy

Strict indication

Meningococcal vaccine, pregnancy

Vaccination should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the foetus.

Meningococcal vaccine, pregnancy

Pregnancy should not preclude vaccination when the risk of exposure is clearly defined

Menotropin [1], pregnancy ---> SmPC of [1] of eMC

Menotropin should not be given during pregnancy

Mepartricin, pregnancy

Mepartricin is intended for male patients only

Mephenytoin, pregnancy

Strict indication

Mepivacaine, pregnancy

Mepivacaine should be given in early pregnancy only if there is not available other local anaesthetic drugs

Mepolizumab [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Nucala during pregnancy. Administration of Nucala to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus.

Meprobamate [1], pregnancy ---> SmPC of [1] of eMC

Meprobamate diffuses across the placenta, and should not be used during pregnancy, especially during the first three months, unless there are compelling reasons

Meptazinol [1], pregnancy ---> SmPC of [1] of eMC

Meptazinol should not be used during pregnancy (apart from labour) unless considered essential by the physician.

Mequitazine, pregnancy

Mequitazine crosses the placental barrier. The use during pregnancy is not recommended

Mercaptamine [1], pregnancy ---> SmPC of [1] of EMA

Mercaptamine should not be used during pregnancy, particularly during the first trimester, unless clearly necessary.

Mercaptopurine [1], pregnancy ---> SmPC of [1] of EMA

Xaluprine should not be given to patients who are pregnant or likely to become pregnant without careful assessment of risk versus benefit

Meropenem [1], pregnancy ---> SmPC of [1] of eMC

As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.

Meropenem/vaborbactam [1], pregnancy ---> SmPC of [1] of EMA

As a precautionary measure, it is preferable to avoid the use of Vabomere during pregnancy.

Mesalazine [1], pregnancy ---> SmPC of [1] of eMC

Mesalazine should be used during pregnancy only when clearly indicated.

Mesna, pregnancy

It should not be used during pregnancy unless clearly necessary

Metacholine, pregnancy

Should not be used in pregnant women unless clearly necessary

Metamizole, pregnancy

Strict indication in the first and second trimester. Contraindicated in the third trimester

Metformin [1], pregnancy ---> SmPC of [1] of eMC

When the patient plans to become pregnant and during pregnancy, diabetes should not be treated with metformin but insulin should be used to maintain blood glucose levels

Metformin/saxagliptin/dapagliflozin [1], pregnancy ---> SmPC of [1] of EMA

Qtrilmet should not be used during pregnancy. If pregnancy is detected, treatment with this medicinal product should be discontinued.

Methadone [1], pregnancy ---> SmPC of [1] of eMC

Methadone should only be used in pregnancy if the physician considers that the potential benefits outweigh the risks.

Methantheline, pregnancy

Strict indication in the third trimester and in the delivery

Methenamine [1], pregnancy ---> SmPC of [1] of eMC

There is inadequate evidence of safety of the drug in human pregnancy but it has been in wide use for many years without apparent ill consequence, animal studies having shown no hazard.

Methionine, pregnancy

Strict indication

Methocarbamol [1], pregnancy ---> SmPC of [1] of eMC

Methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgement of the physician the potential benefits outweigh the possible hazards.

Methotrexate [1], pregnancy ---> SmPC of [1] of EMA

Methotrexate is contraindicated during pregnancy

Methoxsalen, pregnancy

Methoxsalen is contraindicated during pregnancy

Methoxypolyethylene glycol-epoetin beta [1], pregnancy ---> SmPC of [1] of EMA

Caution should be exercised when prescribing to pregnant women.

Methyl aminolevulinate [1], pregnancy ---> SmPC of [1] of eMC

It is not recommended during pregnancy

Methyl aminolevulinate, pregnancy

Not recommended during the pregnancy

Methyldopa [1], pregnancy ---> SmPC of [1] of eMC

If drug therapy is needed in pregnancy, this drug can be used if there is no safer alternative.

Methylergometrine, pregnancy

Contraindicated

Methylnaltrexone [1], pregnancy ---> SmPC of [1] of EMA

Methylnaltrexone bromide should not be used during pregnancy unless clearly necessary.

Methylphenidate [1], pregnancy ---> SmPC of [1] of eMC

Methylphenidate is not recommended for use during pregnancy unless a clinical decision is made that postponing treatment may pose a greater risk to the pregnancy.

Methylprednisolone [1], pregnancy ---> SmPC of [1] of eMC

Methylprednisolone does cross the placenta.

Methylthioninium [1], pregnancy ---> SmPC of [1] of EMA

Methylthioninium chloride Proveblue should not be used during pregnancy unless clearly necessary, e.g. in life-threatening methaemoglobinaemia.

Methysergide [1], pregnancy ---> SmPC of [1] of eMC

Methysergide is contra-indicated during pregnancy.

Metildigoxin, pregnancy

Metildigoxin crosses the placenta. The use in pregnancy should be weighed carefully. It can be only used if the expected benefit to the mother outweighs the potential risk to the foetus

Metipranolol, pregnancy

Strict indication

Metoclopramide [1], pregnancy ---> SmPC of [1] of eMC

This medicine should only be used when there are compelling reasons and is not advised during the first trimester.

Metolazone, pregnancy

Metolazone passes the placenta

Metoprolol [1], pregnancy ---> SmPC of [1] of eMC

It is recommended that metoprolol should not be administered during pregnancy unless it is considered that the benefit outweighs the possible risk to the foetus/infant.

Metreleptin [1], pregnancy ---> SmPC of [1] of EMA

Myalepta is not recommended during pregnancy and in women of childbearing potential not using contraception.

Metronidazole [1], pregnancy ---> SmPC of [1] of eMC

It is contraindicated in 1st trimester and caution in 2nd and 3rd trimester when used to treat trichomoniasis or bacterial vaginosis. For other indications should only be used if benefits outweigh risks or no alternative is available

Metyrapone [1], pregnancy ---> SmPC of [1] of eMC

Metyrapone should not be administered during pregnancy since the drug can impair the biosynthesis of foetal-placental steroids.